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Welcome to the neuro-oncology special issue of JHN Journal. The 
research you’ll find in this issue highlights advancements we have made 
to further advance the science of this difficult field. I’m also pleased to 
report that our division, housed within the Vickie and Jack Farber 
Institute for Neuroscience – Jefferson Health, has continued to make 
great strides in our academic and clinical missions, as well. 
Last year, we met with over 1,500 new patients and performed nearly 
1,000 surgeries. In order to continue to care for these patients in the 
most seamless, multidisciplinary way, we added a third oncologist to 
our division. I’m proud to welcome Nina L. Martinez, MD, to our 
division. Dr. Martinez, an alumna of Jefferson’s neurology residency, 
rejoins us after completing a neuro-oncology fellowship at Memorial 
Sloan Kettering Cancer Center and serving as an attending at Chicago’s 
NorthShore University HealthSystem.
Our skull-base fellowship continues to offer trainees some of the 
country’s most advanced training in the field. The graduates since our 
last neuro-oncology special issue, published two years ago, have 
achieved great success. Varun Khsettry, MD, joined the staff at 
Cleveland Clinic and Alan Siu, MD, is pursuing a second fellowship at 
Semmes Murphey Clinic, one of my alma maters. I’m confident our 
current fellow, Hermes Garcia, MD, will achieve similar success after his 
graduation this summer. 
Finally, I wish to congratulate our division director and departmental 
vice chair, David Andrews, MD, the inaugural Anthony Alfred Chiurco, 
MD, Professor of Neurological Surgery. Dr. Chiurco, SKMC ’67, is a 
practicing neurosurgeon in our area. A few years ago, our colleague 
became a patient of Dr. Andrews when an emergency room visit 
revealed he had a large brain tumor. His generous gift to our division 
will continue to fuel our growth.
None of this would be possible without our ongoing partnership with 
the NCI-designated Sidney Kimmel Cancer Center at Jefferson, 
particularly our colleagues in radiation oncology. As you’ll find as you 
read this issue, we are partners in research, education and clinical care.
Best regards,
 
Christopher J. Farrell, MD 
Assistant Professor of Neurological Surgery  
Vickie and Jack Farber Institute for Neuroscience  
Member, Sidney Kimmel Cancer Center 
 
Dear Reader, 
Christopher J. Farrell, MD
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BRAIN TUMOR TREATMENT AT JEFFERSON 
William W. Keen, a Jefferson physician, performed America’s first successful brain tumor removal in 1888. 
This rich tradition of innovation and excellence continues today in our multidisciplinary brain tumor 
treatment program. 
Our Physicians
The Vickie and Jack Farber Institute for Neuroscience, the home of our brain tumor program, consists of four 
fellowship-trained neurosurgeons, two neuro-oncologists and one medical oncologist working together in 
one center.
They’re joined by our colleagues in the Sidney Kimmel Cancer Center (SKCC) at Jefferson, one of 69 National 
Cancer Institute (NCI)-designated clinical cancer centers for excellence in cancer care and research. We work 
particularly closely with our colleagues in radiation oncology, a department that treats nearly 1,000 cancer 
patients per year. 
Our Resources
Our physicians have access to some of the most advanced technologies available for treating patients with 
brain tumors. This includes both the Visualase® and Neuroblate® MRI-guided laser ablation technologies, a 
GammaKnife™, a Varian True Beam STx Slim LINAC and advanced Brainlab® treatment planning software.
These resources are centered at Jefferson Hospital for Neuroscience (JHN), the Philadelphia area’s only 
hospital dedicated to the treatment of neurological disorders. We’re proud to say JHN has achieved Magnet® 
status, the highest distinction a healthcare organization can receive for excellence in nursing. 
Physicians and basic science researchers from both the Farber Institute and SKCC are engaged in clinical and 
translational research to improve outcomes for people living with brain tumors. Some of these research 
projects include: 
•  ANTISENSE 102, an ongoing immunotherapy clinical trial for glioblastoma developed here  
at Jefferson. 
•  CHECKMATE, a study that examines the efficacy of adding nivolumab to temozolomide and  
radiosurgery for patients with MGMT-methylated glioblastoma. 
•  Our area’s only CAP-accredited brain tumor lab, operated in conjunction with our colleagues  
in the Department of Pathology. 
Educational Opportunities
Thomas Jefferson University, home to the Sidney Kimmel Medical College, is proud to offer both under-
graduate and graduate medical education. We offer: 
•  A third-year clerkship and a fourth-year sub-internship in neurological surgery.  
We are pleased to accept visiting students into the fourth year rotation. For Jefferson  
students, we also offer a fourth year research elective. 
•  An ACGME-accredited residency program training three residents a year. 
•  Multiple fellowships, including an SNS/CAST fellowship in neuro-oncologic surgery,  
with a special emphasis in skull base surgery. 
New Patient Appointments: 1-800-JEFF-NOW  |  Next day appointments usually available
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ABSTRACT  
Purpose/Objectives: Bevacizumab failure is a major clinical problem in the manage-
ment of high grade gliomas (HGG), with a median overall survival of less than 4 months 
(m). This study evaluated the efficacy of fractionated stereotactic re-irradiation (FSRT) 
for patients with HGG after progression on Bevacizumab.
Materials/Methods: Retrospective review was conducted of patients treated with 
FSRT after progression on bevacizumab. A total of 36 patients were identified. FSRT 
was most commonly delivered in 3.5 Gy fractions to a total dose of 35 Gy. Survival 
from initial diagnosis, as well as from recurrence and re-irradiation, were utilized as 
study endpoints. Univariate and multivariate analysis was performed.
Results: Among the 36 patients, 31 patients had recurrent glioblastoma, and 5 patients 
had recurrent anaplastic astrocytoma. The median time from initial bevacizumab 
treatment to FSRT was 8.5 m (range 2.3 – 32.0 m). The median plan target volume for 
FSRT was 27.5 cc (range 1.95 – 165 cc). With a median follow up of 20.4 m, the overall 
survival of the patients since initial diagnosis was also 24.9 m. The median overall 
survival after initiation of bevacizumab was 13.4 months. The median overall survival 
from FSRT was 4.8 m. FSRT treatment was well tolerated with no Grade >3 toxicity.
Conclusions: Favorable outcomes were observed in patients with recurrent HGG 
who received salvage FSRT after bevacizumab failure. The treatment was well 
tolerated. Prospective study is warranted to further evaluate the efficacy of salvage 
FSRT for selected patients with recurrent HGG amenable to FSRT, who had failed 
bevacizumab treatment.
INTRODUCTION 
Malignant gliomas are the most common 
brain tumors, with an estimated yearly 
incidence of 3 per 100,000 people in the 
United States.1 Despite multiple modali-
ties for definitive therapy (which include 
resection, radiation therapy (RT) and 
chemotherapy), these lesions have an 
unfortunately high rate of recurrence.2 
Therefore, even despite recent treat-
ment advances in targeted therapies 
for glioblastoma (GBM) and high grade 
glioma (HGG) such as bevacizumab, the 
long-term outcomes for these patients 
remain poor. 
In modern clinical practice, treatment 
failure of recurrent HGGs largely repre-
sents failure of bevacizumab therapy.3 
In addition to disease recurrence itself 
driving poor outcomes, there is evidence 
that these patients who fail bevacizumab 
also harbor disease that is resistant to 
other systemic therapies.4 Therefore, 
treatment options for these recurrent 
patients remain limited and their prog-
nosis is dismal with a recent review of 
sixteen studies reporting an overall 
survival (OS) of under 4 months after 
bevacizumab failure.4-6
Multiple modalities of radiotherapy have 
been investigated for this population, 
including stereotactic radiosurgery (SRS) 
and brachytherapy. These interventions 
have been shown to have modest utility, 
but with the potential for significant 
associated toxicity. In that context, frac-
tionated stereotactic radiotherapy (FSRT) 
is a promising treatment modality for the 
treatment of these refractory HGGs. This 
modality possesses the precise targeting 
advantages of SRS but with the dose-
sparing radiobiologic properties of 
fractionation to allow greater sparing 
of surrounding critical structures, thus 
limiting toxicity.7,8 Taken together, 
FSRT therefore possesses the potential 
for decreased toxicity as compared to 
SRS while still providing excellent local 
control.9 The present study sought 
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(intensity modulated radiation therapy) or 
hybrid-Arcs (Brainlab, Munich, Germany), 
a combination of dynamic arcs with IMRT 
beams. The patients were treated with 
FSRT to a median PTV dose of 35 Gy 
delivered in 3.5 Gy fractions.10 The dose 
was reduced to 30 Gy in 3 Gy fractions 
for large targets, and high critical normal 
structure dose. The constraints for normal 
critical structures include: brainstem max 
dose <20 Gy; optic nerve max dose < 15 
Gy, chiasm max dose < 15 Gy. 
Statistical analysis 
The primary end point of the study was 
overall survival from initial diagnosis, as 
well as survival from first recurrence and 
re-irradiation (described in greater detail 
under Statistical Analyses). Toxicity was 
also graded using Radiation Therapy 
Oncology Group (RTOG) criteria. Overall 
survival was defined as the time from 
initial diagnosis to the time of death. Date 
of recurrence was defined as the date of 
radiographic evidence of progression. 
Survival from recurrence and from reir-
radiation were therefore defined as the 
time from this radiologic evidence or 
radiation therapy until death, respectively. 
Kaplan–Meier curves were generated for 
the overall survival endpoint. Cox propor-
tional hazard modeling was used for 
multivariate analysis with factors analyzed 
in a step-wise fashion. All statistical anal-
ysis was performed using the STATA data 
analysis and statistical software version 
13.1 (STATA Corporation).
to evaluate the safety and efficacy of 
FSRT in patients who failed therapy with 
bevacizumab. 
MATERIALS AND METHODS
Patients
The Thomas Jefferson University insti-
tutional review board approved this 
single-institution, retrospective study. 
Patients who received FSRT salvage 
after progression on bevacizumab were 
included. A total of 36 patients were iden-
tified from 2006 to 2013. Patients who 
received FSRT within 2 months of initiation 
of bevacizumab were excluded. Patients 
were followed with MRI scans and clinical 
assessment, which were obtained 6 to 8 
weeks after FSRT and at approximately 
2-month intervals thereafter.  
Treatment Planning 
Treatment decisions were based on 
consensus recommendations following 
discussion in our institution’s multidisci-
plinary brain tumor board consisting of 
radiologists, neurosurgeons, neuro-oncol-
ogists, neuropathologists and radiation 
oncologists. Prior to 2004, treatment plan-
ning was conducted with the X-knife 3-D 
planning system (Radionics, Burlington, 
MA, USA), which delivered 6 MV photons 
with a dedicated stereotactic 600SR linear 
accelerator (Varian, Palo Alto, CA, USA). 
From 2004 to 2013, treatment planning 
was carried out with Brain Lab (Novalis) 
using mMLC leaves with a leave thickness 
of 3 mm and Exac Trac on board imaging. 
All patients undergoing irradiation were 
fitted with custom-made Brainlab (Munich, 
Germany) thermal plastic masks for 
immobilization. Treatment planning MRI 
and computed tomography (CT) images 
were obtained and fused. All patients had 
thin cut (1-1.5 mm) fat suppressed coronal 
post-contrast MRI. The gross tumor 
volume (GTV) was defined on MRI using 
the gadolinium enhanced T1 weighted 
series, as peripherally enhancing tissue. 
Surrounding edema was not purposely 
included in the treatment volume. The 
planning target volume was the GTV with 
minimum margin (0-2 mm per the treating 
physician). Critical normal structures, such 
as optic nerves, chiasm, and brainstem 
were also contoured. Treatment plan-
ning was carried out with Brain Lab Iplan 
(Munich, Germany). The radiation plan-
ning used dynamic conformal arcs, IMRT 
JHN JOURNAL 
RESULTS
Patient Population and Treatment 
Parameters
We identified 36 patients with either 
anaplastic astrocytoma (5 patients) or 
glioblastoma multiforme (GBM) (30 
patients) who had clinical and radio-
graphic evidence of tumor progression on 
bevacizumab and received FSRT between 
2006 and 2013 (Table 1). One patient 
had gemistocytic astrocytoma. Patient 
characteristics are listed in Table 1. There 
were 17 males and 19 females. All patients 
received initial surgery and were treated 
with radiation and temozolomide. The 
median age at recurrence was 57.1 years 
(range 37-73). The median Karnofsky 
Performance Status at recurrence was 
80%. Following disease progression on 
bevacizumab, the median target volume 
treated with FSRT was 27.5 cc (range 
1.95 – 165 cc). The median dose was 
35 Gy (range, 30 Gy – 37.5 Gy). 
Survival
Patients underwent routine surveillance 
for a median follow up of 20.4 m after 
initial diagnosis, with an overall survival 
from initial diagnosis of 24.9 m. Upon 
evidence of initial disease recurrence, 
patients were promptly started on beva-
cizumab. The median overall survival 
after initiation of bevacizumab was 13.4 
months. The median time from initial 
bevacizumab treatment to initiation of 
Table 1.  Patient Demographic and Treatment Information. Descriptive data on our study cohort is 
shown, encompassing demographic data, clinical information and treatment information.
Number of patients 36
Gender
Male 17
Female 19
Median Age at FSRT salvage (range) 56 years (37-73)
Median KPS at FSRT salvage (range) 80 (50-100)
Histology at Recurrence
GBM 30
Anaplastic glioma 4 (3-4)
Other 2 (1-2)
Median Volume of Recurrence (range) 27.5 cc (1.95-165)
Median Radiation Dose (range) 35 Gy (30-37.5)
Median time from Bev to FSRT (range) (2.4-32.1)
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in patients with high-grade gliomas, 
treatment failure and disease progres-
sion while on bevacizumab remain as 
an unfortunate reality in managing these 
patients. Therefore, overall prognosis 
remains quite poor.  Despite this clinical 
need, there remains a paucity of literature 
regarding the management of patients 
who fail bevacizumab. In that context, 
the present study investigated FSRT as a 
potential treatment modality to address 
this problem.
Prior to FDA-approval of bevacizumab, 
FSRT had been previously studied in the 
setting of recurrent HGG, with generally 
favorable results. Multiple studies have 
shown FSRT to be efficacious, with OS in 
these studies ranging from 5-11 months. 
Moreover, these studies showed FSRT to 
be very well tolerated, with a low rate of 
grade 3 toxicities, radiation necrosis (RN) 
and reoperation.10-12
Of note, one study (Lederman et al.) 
observed significantly more toxicity and 
reoperation (11 of 88 patients) than the 
others. This toxicity outlier can perhaps 
be explained by the use of a different 
dosing regimen (24 Gy in 4 fractions in 
Lederman et al. versus 30-35 Gy in 6-10 
fractions in the other studies).13  In a head 
to head trial, Patel et al. compared stereo-
tactic radiosurgery (SRS) with FSRT and 
showed comparable overall survival and 
radiographic tumor response between 
the two modalities, with a trend towards 
fewer events of radiation necrosis (RN) in 
the FSRT cohort.14
The data on FSRT treatment following 
bevacizumab failure is much more 
limited. In a retrospective study, Torcu-
ator et al. looked at two cohorts of 
patients who failed bevacizumab: one 
that received either FSRT or SRS and one 
that received no FSRT/SRS. They demon-
strated an increased overall survival in 
patients receiving FSRT/SRS (7.2 vs 3.3 
months in untreated patients). Another 
study that is published only in abstract 
form by Nehaw et al. similarly looked at 
RT (including 6 patients who received 
FSRT) versus non-RT regimens following 
bevacizumab failure and showed statisti-
cally significant increased survival in the 
radiation group (8.8 vs. 5.4 months for 
untreated). Despite this small body of 
literature, neither of these studies inves-
tigated FSRT alone after bevacizumab 
p=0.04). Additionally, there was a trend 
towards significance for re-resection 
status associated with OS from FSRT (HR 
1.87 p=0.17).
Toxicity
No patients demonstrated clinically 
significant acute morbidity, with no grade 
III or higher toxicity observed. All patients 
were able to complete the prescribed 
radiation course without interruption. 
There were no observed hospitalizations 
or surgeries for early acute or delayed 
toxicity in the study population. 
DISCUSSION
Despite recent advances such as bevaci-
zumab that have extended overall survival 
salvage FSRT was 8.5 m (range 2.4 – 32 m), 
and the median overall survival after FSRT 
was 4.8 m. Data are presented in table form 
(Table 2) as well as in the form of a Kaplan-
Meyer survival curve (Figure 1).
Multivariate Analysis
Multivariate analysis was performed to 
investigate whether different variables 
in our study population influenced OS 
from recurrence or from FSRT therapy 
(Table 3). These included age at recur-
rence, KPS score, volume of recurrence, 
histology (AA vs GBM) or re-resection 
status. Importantly, out of all of these 
variables, only re-resection demonstrated 
a statistically significant association with 
overall survival from recurrence (HR 2.59; 
Figure 1.  Kaplan-Meyer Overall Survival Curve. 
Graph displays OS from the time diagnosis for patients who went on to fail bevacizumab 
therapy and require FSRT in our study cohort.
0 20 40 60 80 100
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100
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l
Table 2.  Survival Statistics. Survival data accrued from the study cohort is shown, expressed as 
OS from diagnosis, recurrence and from FSRT. 
Median Overall Survival (Range)
From Diagnosis 24.9 months (11.4-94.2)
From First Recurrence 12.0 months (4.2-49.1)
From FSRT 4.8 months (0.5-23.4)
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failure, nor did they report on safety or 
toxicity of these approaches. 
In that context, the present study 
represents one of the first studies 
to specifically investigate the role of 
FSRT in the context of bevacizumab 
failure. Indeed, our work builds off of 
previous work by both our group and 
others showing comparable benefit and 
improved safety in FSRT regimens for 
HGGs as compared to SRS for treatment 
of HGG in other contexts.10,11,13 Specifi-
cally, the present study demonstrates 
the feasibility, efficacy and tolerability 
of such an approach in patients who fail 
bevacizumab. 
One limitation of our study is the lack of 
a control cohort for comparison in terms 
of outcomes to put our overall survival 
into context. Historically, patients who 
fail bevacizumab have been shown in a 
recent review of sixteen studies to have 
an overall survival of 3.8 months.4-6 
Thus, our observed overall survival 
compares favorably to, and indeed 
exceeds that mark. Taken in the context 
of the aforementioned studies which 
show benefit of RT vs. no RT in bevaci-
zumab failure, and also that FSRT and SRS 
provide similar OS in recurrent gliomas 
before bevacizumab treatment, our data 
are consistent with these previous studies 
and moreover suggest a role for FSRT in 
the management of patients who fail 
bevacizumab. Despite our findings, it is 
worth noting that one limitation of our 
study is the potential bias of our dataset 
in that it only includes patients who are 
amenable to therapy with FSRT. There-
fore it is difficult to directly compare our 
survival data to the existing literature, 
given that the literature includes all 
patients, whether or not they are eligible 
for FSRT. Further head-to-head studies 
will be needed to evaluate FSRT versus 
other modalities to definitively establish 
a role and identify populations that would 
most benefit. 
Notably, our multivariate analysis yielded 
only one variable that was associ-
ated with overall survival: re-resection 
status. Indeed, there is controversy in 
the literature regarding the prognostic 
value of re-resection in patients with 
recurrent HGG,2 but our data suggest 
that re-resection is actually deleterious 
in terms of survival outcomes. However, 
given the retrospective nature of the 
current study, it is difficult to draw strong 
conclusions from these data, as re-resec-
tion status itself may be confounding by 
representing underlying patient charac-
teristics that lead to poorer prognosis. 
Future studies will be needed to identify 
patient populations who will most benefit 
from an FSRT regimen. 
Other limits to our study include a small 
patient cohort (36) as well as those short-
comings inherent to all retrospective 
studies including selection bias and 
potential treatment differences in a 
non-randomized study. Despite these 
potential drawbacks, this study repre-
sents, to our knowledge, the largest 
literature cohort of FSRT patients in the 
context of bevacizumab failure. More-
over, the dire prognosis of these patients 
and the paucity of data regarding their 
management underscores the relevance 
of the present study, and suggests the 
need for future prospective randomized 
trials to improve survival and positively 
impact the lives of patients with HGG.
CONCLUSIONS
Favorable outcomes were observed using 
FSRT to treat patients with recurrent HGG 
and the treatment was well tolerated. 
Prospective study is warranted to further 
evaluate the efficacy of salvage FSRT for 
patients with recurrent HGG after beva-
cizumab failure.
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ABSTRACT
Background: Extending a previous Phase I study, we report the results of a second 
Phase I autologous tumor cell vaccination trial for patients with recurrent glioblastomas 
(IND 14379-101, NCT01550523).
Methods: Following surgery, subjects were treated by 24 hour implantation in the 
rectus sheath of ten biodiffusion chambers containing irradiated autologous tumor cells 
and IGF-1R AS ODN with the objective of stimulating tumor immunity. Patients were 
monitored for safety, clinical and radiographic as well as immune responses.
Results: There were no Grade 3 toxicities related to protocol treatment and overall 
median survival from initial diagnosis was 91.4 weeks. Two protocol survival cohorts 
with median survivals of 48.2 and 10 weeks were identified and predicted by our 
pre-treatment assessments of immune function, corroborated by post-vaccination 
pro-inflammatory cytokine profiles. Longer survival subjects had imaging findings 
including transient elevations in cerebral blood volume (rCBV) and sustained elevations 
of apparent diffusion coefficient (ADC) interpreted as transient hyperemia and cell loss. 
Conclusions: The vaccine paradigm was well-tolerated with a favorable median 
survival. Our data support this as a novel treatment paradigm that promotes anti-tumor 
immunity.
KEYWORDS
Decompressive Hemicraniectomy, Intracerebral Hemorrhage, Malignant MCA Stroke, 
Traumatic Brain Injury, Aneurysmal Subarachnoid Hemorrhage, Intracranial Pressure, 
Herniation
INTRODUCTION
WHO Grade IV astrocytoma (glioblastoma) is a uniformly fatal primary intracranial malig-
nancy with a median survival of 14 months.1 We conducted an earlier pilot Phase I vaccine 
trial in patients with high grade astrocytomas2 and designed a replacement Phase 1 trial 
with optimized reagents, expanded radiographic response criteria, and new exploratory 
objectives.
METHODS
Study Site and Patients
The study was conducted at Thomas Jefferson University and reached target accrual 
of 12 patients in 14 months. Criteria for enrollment included age > 18, a Karnofsky 
performance score of 60 or better, and 
no co-morbidities that would preclude 
elective surgical re-resection. Twelve 
patients were enrolled for treatment after 
failure from standard therapy.1 A summary 
of enrolled patients, and all available perti-
nent data is included in Table 1.
Study Design and Objectives
As before, the combination product 
consisted of autologous tumor cells 
removed at surgery then treated over-
night with the IGF-1R AS ODN (4mg/ml) 
prior to being added to semi-permeable 
chambers and irradiated.2 Enhance-
ments to the vaccine product included 
use of an 18-mer IGF-1R AS ODN with 
the sequence 5’-TCCTCCGGAGC-
CAGACTT-3’, two frameshifts upstream 
from the previous sequence; and, based 
on data showing that the AS ODN has 
immunomodulatory properties,3,4 addi-
tion of 2 mg of exogenous antisense to 
the chambers (C-v). The protocol was 
also amended to include an eleventh 
control chamber containing PBS (C-p). 
Study objectives included assessment 
of safety and radiographic responses as 
well as exploratory objectives looking at 
immune function and response.
Radiological Assessments
Serial imaging assessments were 
performed on Philips 1.5T and 3T MRIs 
and GE 1.5 T MRIs. Routine anatomic MRI 
features were evaluated as well as physi-
ologic measurements including dynamic 
susceptibility weighted (DSC) MR perfu-
sion and 15-direction diffusion tensor 
imaging (DTI) were also utilized. 
Immunological Assessments
Plasma leukopheresis was performed 
one week before surgery for baseline 
assessment of immune function. Blood 
David W. Andrews, MD1; Kevin D. Judy, MD1; Larry A. Harshyne, PhD1; 
D. Craig Hooper, PhD2
1Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA 
2Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA
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rated as low, moderate and strong and 
staining patterns described as focal or 
diffuse.
Cytokine/chemokine levels in tumor cell 
supernatant were analyzed by Luminex 
kits as designated above. Membranes 
from paired vaccine and control cham-
bers were embedded in paraffin for 
standard immunohistopathologic exami-
nation. Post-mortem autopsy was limited 
to examination of the brain and findings 
were compared to archival paraffin 
blocks of previously treated or untreated 
glioblastomas diagnosed at autopsy.
Statistical Analysis
The level of statistical significance 
between quantitative measures in 
different samples was determined by a 
two-tailed unpaired t-test or matched 
pairs t-test with p < .05. Survival analysis 
was performed by Kaplan-Meier analysis 
and significance established by log 
rank comparisons. All statistical analysis 
including mixture discriminant analysis 
was performed with JMP v. 11 software 
(SAS, North Carolina).
12-myristate,13 acetate (PMA) and iono-
mycin as previously described.6 PBMC 
from glioblastoma patients and normal 
donors were cultured for 24 hours at 37°C 
and 5% CO2 in AIMV media containing 
10% fetal bovine serum (Gibco). Non-
adherent lymphocytes were transferred 
to new plates in order to eliminate 
non-specific effects of contaminating 
monocytes. Lymphocyte cultures were 
stimulated with phorbol 12-myristate 
13-acetate (PMA, 100 ng/ml) and iono-
mycin (0.1 mM, both from Sigma-Aldrich) 
for 18 hours. BD Golgiplug™ (1:1000, 
Brefeldin A, BD Bioscience) was added 
during the last 6 hours of culture to 
permit cytokine accumulation. 
Tumor tissue sections were assessed 
by immunohistochemistry or immuno-
fluorescence, adapting the method of 
Emoto7, for GFAP, IGF-1R, CD163, CD14, 
CD3, CD4, and CD8. Immunopositive 
cells were counted quantitatively with 
Aperio or qualitatively by an experienced 
neuropathologist (LEK) using an ordinal 
scale from 0 (no staining) to 6 (strong 
diffuse staining) with staining intensity 
was obtained post-operatively on days 
7, 14, 28, 42, 56, and every 3 months 
after vaccination. Sera and cell fractions 
were separated by centrifugation and 
cells were treated with red blood cell 
lysis buffer and white blood cells either 
quantified by flow cytometry or stored 
in DMSO at -80°C. Serum samples were 
also stored at -80°C. Flow cytometry 
was performed as previously described5 
using an EasyCyte 8HT (Millipore) and 
fluorescently-conjugated mAb specific 
for human CD4, CD8,CD11b, CD14, 
CD16, CD20, CD45, CD56, CD80, CD83, 
and CD 86 (all from BD Biosciences), and 
CD163 (R&D Systems). Post- collection 
analysis was performed with FlowJo 
software (Tree Star Inc, Ashland, OR). 
Serum cytokine factors were quantified 
using Luminex bead arrays (human cyto-
kine/chemokine panels I, II, and III from 
Millipore and HCMBMAG/ MILLIPLEX 
Mag Cancer multiplex assay (emdmilli-
pore.com). This included 6 serum markers 
for glioma related to stem cell function 
including DKK-1, NSE, Osteonectin, 
Periostin, YKL-40, and TWEAK. T-cell 
stimulation was performed with phorbol 
Table 1.  Summary of Patients Enrolled.
Subject Age KPS Interval between 
surgeries (weeks)
# chambers 
implanted
Original lymphocyte 
count (cells/mm2)
Lymphocyte count 
at enrollment 
(cells/mm2)
Previous 
treatments
IDH-1 mutation/ 
MGMT methylation
TJ01 39 70 177 10 N/A 400 S,RT + TMZ, Bev -/
TJ02 57 80 90 9 N/A 1570 S,RT + TMZ -/methylated
TJ03 75 70 32 7 700 300 S,RT + TMZ -/
TJ06/R1 66 80 54 8 2000 1300 S,RT + TMZ -/
TJ07 43 80 215 10 500 430 S, RT + TMZ, 
Bev; RTOG 0525
+/
TJ08 55 80 52 8 1000 500 S,RT + TMZ -/
TJ09 57 80 61 7 1400 300 S, RT + TMZ, 
RTOG 0929
-/unmethylated
TJ10 47 60 376 7 N/A 1800 S, RT + TMZ, Bev -/methylated
TJ11 39 70 32 11* 2400 200 S, RT + TMZ -/
TJ12 60 80 74 7 1100 600 S, RT + TMZ, 
Panobinostat
-/
TJ13 64 80 182 11 N/A 2100 S, RT + TMZ -/
TJ14/R 77 90 30 7/11 1800 1100 S, RT + TMZ -/unmethylated
1Compassionate retreatment; *Protocol amendment to include control chamber filled with phosphate buffered saline; S: surgery; RT: radiation therapy; 
TMZ: temozolamide chemotherapy; Bev: bevacizumab chemotherapy; IDH-1: isocitrate dehydrogenase-1
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Actual CD4 and CD8 T cell counts as well 
as DC counts were significantly higher in 
the longer cohort compared to the short 
cohort. There was a significant correlation 
between CD4 and DC cells and between 
CD4 and CXCL12 only in the longer 
cohort. Coordinated changes between 
circulating levels of T cells, monocytes, 
and pro-inflammatory chemokines/cyto-
kines after vaccination were seen in three 
of four longer cohort subjects. 
As a distinguishing feature differentiating 
the cohorts, peripheral blood cells from 
the longer survival subjects manifested 
significantly higher Th-1 cytokine produc-
tion including IFN-g after stimulation with 
PMA and ionomycin from PBMC obtained 
on day 14. 
Levels of circulating lymphocytes were 
significantly decreased (p<0.0001) in all 
GBM patients when compared to normal 
subject samples (Figure 1A, left panel) and 
the medians of both patient populations 
fell outside of the normal range (Figure 
1A, gray lines). Patients in this same cohort 
exhibited significantly higher levels of 
monocytes (Figure 1A, right panel, p<0.05), 
but the medians of these cell populations 
fell within normal range. 
The mere presence of a given cell 
subset is not enough to ensure proper 
immune function. The cell must also be 
able to respond to stimuli and produce 
at the primary tumor site and slower 
progression. Examples of anatomic 
responses in both cohorts is included 
noted in Figure 2A&B. Physiologic MRI 
measurements augmented these anatomic 
observations for both cohorts is featured 
in Figure 2C&D. Sequential DSC MR perfu-
sion was performed in 7 patients, including 
3 longer-term survivors (TJ03, TJ06, and 
TJ09) who had a paradoxical increase in 
rCBV while improving clinically; however, 
this effect was transient and there was 
a more sustained decrease in rCBV. 
Sequential 15 directions DTI data included 
two long-term survivors (TJ03 and TJ06) 
who showed ADC values increasing in the 
affected hemisphere, reflecting loss of 
tumor cellularity associated with disease 
regression. 
Immunologic Response 
Assessments after Vaccination by 
Survival Cohort
Levels of 24 of the 78 cytokines/chemo-
kines assessed were significantly higher 
in serum from the longer survival cohort 
compared to the short cohort. A spike in 
serum CCL2 occurred after surgery but 
was absent at re-operation in two patients. 
CCL2 levels remained significantly higher 
throughout the post-operative period in 
the short survival cohort. These post-
operative spikes were highly correlated 
with TNF-a spikes. (data not shown).
RESULTS
Safety Assessment and Clinical 
Course
Only one SAE was related to the protocol 
(femoral vein thrombosis after leuko-
pheresis). Nine patients succumbed to 
tumor progression while three patients 
died from other causes. Five autopsies 
were performed.
Median overall survival from initial diag-
nosis was 91.4 weeks which compared 
favorably to other recurrent glioma 
immunotherapy trials.8-13 Two signifi-
cantly different protocol survival cohorts 
of 48.2 and 10 weeks were identified 
as longer and short survival cohorts, 
respectively (Figure 1A&B). Excluding 
one outlier (TJ03), we documented a 
significant correlation between protocol 
survival and degree of lymphopenia at 
enrollment (Figure 1C). Comparison of 
CBC values at initial diagnosis and at 
protocol enrollment indicated that the 
mean lymphocyte count had dropped 
significantly (65%) after standard therapy 
(N=8, p = .012, paired t-test). 
Radiographic Responses
Routine MRI features were assessed 
as previously described.2 In the longer 
survivors we noted diminished size 
of enhancement and FLAIR envelope 
Figure 1.  Survival Metrics.
A. Overall survival of patients in trial; B. protocol survival with two survival cohorts; Nine patients died of disease progression while one died 
of intracerebral hemorrhage and two of sepsis. Overall protocol survival was 48.2 weeks and 9.2 weeks, respectively for longer (N = 4) and 
short (N = 8) survival cohorts (log-rank = .014). C. Excluding one outlier and three non-disease-related deaths linear regression revealed high 
correlation between protocol survival and lymphocyte count at enrollment (R2 = .8, p = .0028).
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(Figure 1C, left panel). Furthermore, 
recursive partitioning analyses identified 
two different populations (R2=0.547) of 
recurrent GBM patients enrolled in our 
clinical trial (Figure 1C, right panel). 
Reanalyzing these data focusing on 
single parameters based on the func-
tional immune capacity confirmed the 
highly significant differences identified 
by recursive partitioning (Supplementary 
Figure 1). Patients with higher immune 
function possessed 3-fold higher levels of 
lymphocytes (p<0.0001) and half as many 
monocytes (p<0.005) when compared to 
the lower functioning group (Supplemen-
tary Figure 1). In addition to higher levels 
of lymphocytes, the T cells from patients 
with higher immune function produced 
twice as much IFN-g following stimulation 
patients with primary and recurrent GBM 
produced significantly less IFN-g when 
compared to normal controls (p< 0.01), 
but there was no difference between 
GBM patient cohorts (Figure 1B, right 
panel). 
Moreover, while a difference in the 
quantity of IFN-g produced by the T cells 
was observed, there was no difference in 
the frequency of IFN-g+ T cells between 
these two cohorts (data not shown). In 
order to assess the relationship between 
lymphocyte numbers and immune func-
tional capacity, we performed linear 
regression analyses. Lower levels of 
circulating lymphocytes are associated 
with a statistically significant (R2=0.508, 
p=0.0093) decrease in IFN-g production 
following PMA/ionomycin stimulation 
appropriate immune modulators. 
T-helper type 1 immunity is consid-
ered to be the appropriate anti-tumor 
immune response. Cultures of non-
adherent lymphocytes were stimulated 
nonspecifically with phorbol 12-myristate 
13-acetate (PMA) and ionomycin over-
night in order to stimulate the production 
of IFN-g, the prototypical Th1 cytokine 
which was detected by intracellular 
cytokine flow cytometry. Viable, CD3+ 
T cell-specific gates were established 
(Figure 1B) and the median fluorescence 
intensity (MFI) of IFN-g+ T cells was 
normalized to T cells that did not produce 
cytokine (IFN-g+ T cells). PMA/ionomycin 
stimulation of normal T cells resulted in a 
26-fold increase in the IFN-g MFI (Figure 
1B, right panel). T cells enriched from 
Figure 2.  Radiographic responses with associated physiologic measurements and cytokine profiles.
A. Examples of short survival cohort. TJ11: A-D; TJ10: E-H. A,E: pre-operative T1-gadolinium-enhanced axial images; G: T1-gadolinium-
enhanced coronal image; C: pre-operative axial FLAIR image. B,D,F,H: respective 3 month post-operative images. B. Examples of longer 
survival cohort. TJ06: A-D: TJ09: E-H. A,E: pre-operative T1-gadolinium-enhanced axial images; C,F: pre-operative axial FLAIR images. 
B,D,F,H: respective 3 month post-operative images. C. Relationship between relative cerebral blood volume in tumor v. apparent diffusion 
coefficient in short survival cohort. D. Relationship between relative cerebral blood volume in tumor v. apparent diffusion coefficient in 
longer survival cohort; there is a high correlation between the ADC and rCBV (R2 = .96, p = .0005).
	
A B C
D
14
JHN Journal, Vol. 13 [2018], Iss. 1, Art. 7
https://jdc.jefferson.edu/jhnj/vol13/iss1/7
DOI: https://doi.org/10.29046/JHNJ.013.1
11JHN JOURNAL 
Recurrent Glioblastoma 
Figure 3.  Functional immune capacity varies in glioblastoma patients.   
A. Lymphocyte and monocyte frequencies are expressed as a percentage of white blood cells as determined by clinical blood counts 
performed by Thomas Jefferson University Hospital. Frequencies in trial patients are compared to primary glioblastoma patients and 
normal blood donors. Scatter dot plots indicate the mean frequency and standard deviation. Statistical significance of differences between 
tumor patients and normal blood donors were assessed by ANOVA followed by Dunnett’s post-test (****p<0.0001 and *p<0.05). Gray 
lines represent the upper and lower range of normal values. GBM signifies newly diagnosed patients; GBMr signifies recurrent glioblastoma 
patients. B. Non-adherent peripheral blood mononuclear cells were stimulated with PMA/ionomycin and cytokine production was assessed 
by intracellular flow cytometry. Live cell gates were established in forward- and side-scatter plots (left panel). Quadrant gates were used 
to assess IFN-g production in CD3+ T lymphocytes (middle panel). Numbers indicate the frequency of cells in a given quadrant. Median 
fluorescence intensity of IFN-g +CD3+ cells was normalized to IFN-g -CD3+ cells and is presented as a ratio in scatter dot plots (right panel). 
Statistical significance of the difference between tumor patients and normal blood donors was assessed by ANOVA followed by Dunnett’s 
post-test (***p<0.0005). C. Left panel: Recursive partitioning analysis separated the trial patients into groups with higher and lower 
immune functional capacity (R2=0.547). Right panel pair: Linear regression analysis of IFNg production versus peripheral blood lymphocyte 
frequency revealed a significant association of these variables only in the longer survival cohort with a positive correlation (R2=0.83).  
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Evolution of resistance to treatments in 
gliomas has now been associated with 
activation of the IGF-1R signaling axis 
and IGF-1R inhibition through a small 
molecule inhibitor overcomes this resis-
tance with improved outcomes.23 We 
are currently exploring the impact of the 
IGF-1 bioregulatory system in recurrent 
gliomas and the impact of the IGF-1R AS 
ODN in this vaccination paradigm. 
Differences in the radiographic obser-
vations between the longer and short 
survival patient cohorts provide further 
support for the concept that the vacci-
nation paradigm may have an impact on 
the glioma TME. Higher rCBV values are 
typically associated with tumor progres-
sion,24 and MR perfusion had only 
transient increases in the longer cohort, 
a finding not previously described. ADC 
measurements differentiated tumor 
progression (lower values) from what we 
interpreted as cell loss (higher values).25 
In summary, we have established the 
safety profile of an improved combina-
tion glioma vaccine product and have 
documented alterations in immune 
parameters associated with clinical and 
radiographic improvements. Despite 
immune compromise, we documented 
favorable immune responses associated 
with tumor regression and longer survival 
after treatment. To be most effective, 
however, a replacement trial should 
include screens for immune compromise 
and means by which immune function 
could be restored prior to vaccination.
Study Oversight
The physician sponsor (DWA) was 
primarily responsible for the design 
and funding of the study. All authors 
participated in the conduct of the study, 
analysis of the data and the reporting of 
the results. After IRB approval, this study 
was overseen by an independent data 
safety and monitoring board appointed 
by the Sidney Kimmel Cancer Center at 
Thomas Jefferson University.
DWA and DCH have financial interests in 
the Imvax Corporation related to this work. 
higher levels of tumor-specific antibody 
isotypes and cytokines/chemokines 
commonly associated with Th1 immu-
nity including IgG1, IgG3, IL12, CXCL10, 
CXCL12, CCL7, CCL19, and CCL21 not 
seen in the short cohort. 
The short survival cohort had longer 
overall survival perhaps in part due to 
MGMT methylation and better responses 
to temozolamide in three patients. 
However the treatment-induced lympho-
penia and the lower CD4:CD8 ratio could 
perhaps also be ascribed to temozol-
amide. Also, elevated serum CCL2 levels 
found in the short cohort have been 
associated with the mesenchymal gene 
expression profile19 and a poor prog-
nosis20 in glioma patients.
Cytokine production is a hallmark feature 
of immune function in lymphocytes. We 
used phorbol ester-mediated, non-specific 
stimulation of patient lymphocytes in order 
to stimulate maximal cytokine output as a 
surrogate indicator of immune function. 
IFN-g is the classical Th1 cytokine and the 
logical choice for assessing immune fitness 
of T lymphocytes in our GBM patients. 
The amount of IFN-g production by T 
cells following overnight stimulation was 
approximately half the amount produced 
by normal donor cells treated similarly. 
IFN-g production and lymphocyte counts 
were strongly associated and predictively 
identified patients with different levels of 
immune fitness that fell into either the 
longer or short survival cohort. Lympho-
cytes from patients with higher functional 
immune capacity were more frequent 
and produced higher levels of IFN-g that 
approached levels to those produced by 
normal lymphocytes stimulated under 
similar conditions. In contrast, T cells from 
trial patients in the lower immune func-
tion cohort were less in number (50%) and 
unable to respond to PMA stimulation. 
The implanted chambers have inherent 
adjuvanticity. We have confirmed that the 
antisense sequence, its CpG motif, and 
the direct mixture with glioma cells in situ 
effectively initiate anti-tumor immunity3 
also noted by others.21,22 The CpG motif 
specifically interacts with TLR94 causing 
plasmacytoid DC activation, measured 
by CD80 and CD86 expression.5 The 
elevated CD4:CD8 ratio after vaccination 
in the longer survival cohort could reflect 
local TLR9 DC activation and CD4 T cell 
stimulation. 
with PMA/ionomycin (Supplementary 
Figure 1, p<0.01). Subsequent analyses 
will focus on patients with higher/lower 
functional immune capacity. Analysis of 
hospital-acquired blood cell counts fail 
to take in to consideration immune cell 
subsets. We performed flow cytometry 
phenotyping in order to further charac-
terize the white blood cells. Frequencies 
of CD20+ B cells were significantly 
decreased in those patients with lower 
cohort (p<0.005) and fell outside of the 
normal average (Figure 2). CD4+ T cells 
in both cohorts were significantly lower 
than the normal average, while CD14+ 
monocytes were significantly increased 
compared to normal averages (Figure 2) in 
both partitioned cohorts. CD8+ T cells in 
both cohorts were similar to normal aver-
ages (Figure 2). There was no difference 
between the lower and higher cohorts 
with respect to CD4+ or CD8+ T cell, or 
CD14+ monocyte frequencies (Figure 2). 
DISCUSSION
Like its predecessor, the revised 
autologous cell/chamber-based GBM 
vaccination trial did not raise any signifi-
cant safety concerns. We recognized, 
however, that an immunotherapy trial 
for recurrent GBM faces incumbent chal-
lenges. Patients emerging from standard 
therapy for GBM often have severe leuko-
penia,14 which was also documented in 
the current trial. It was therefore not 
surprising that we could not docu-
ment T cell infiltrates in the TME after 
treatment. Surgery itself enhances host 
immune mechanisms favoring tumor 
growth through the attraction of M2 
macrophages to the tumor environment 
postoperatively15,16 suggested by the CCL2 
serum spike provoked by craniotomy. 
Other than this post-operative serum 
spike, the highest levels of CCL2 expres-
sion were found in the tumor supernatants 
during vaccine preparation supporting 
well-documented observations that CCL2 
is produced from cells in the TME.17,18 The 
lack of a CCL2 peak after re-vaccination in 
two patients suggested loss of these cells 
after the first vaccination.
We identified two significantly different 
survival cohorts with different responses 
to this vaccine paradigm allowing us to 
explore the nature of potentially thera-
peutic immune mechanisms. Serum from 
the longer cohort subjects contained 
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ABSTRACT
Purpose: We performed a phase I study to determine the maximum tolerable dose 
(MTD) and safety of ipilimumab with stereotactic radiosurgery (SRS) or whole brain 
radiotherapy (WBRT) in patients with brain metastases (BM) from melanoma.
Methods: Based on intracranial (IC) disease burden, patients were treated with WBRT 
(Arm A) or SRS (Arm B). Ipilimumab starting dose was 3 mg/kg (every 3 weeks, starting 
on day 3 of WBRT or 2 days after SRS). Ipilimumab was escalated to 10 mg/kg using a 
two-stage, 3+3 design. The primary endpoint was to determine the MTD of ipilimumab 
combined with radiotherapy. Secondary endpoints were overall survival (OS), IC and 
extracranial (EC) control, progression free survival (PFS), and toxicity. This trial is regis-
tered with ClinicalTrials.gov, number NCT01703507.
Results: Characteristics of the 16 patients enrolled between 2011 and 2014 were: mean 
age, 60; median BM, 2 (1 to >10); number with EC disease, 13 (81%). Treatment included 
WBRT (n=5), SRS (n=11), ipilimumab 3mg/kg (n=7), 10 mg/kg (n=9). Median follow-up 
was 8 months (Arm A) and 10.5 months (Arm B). There were 21 grade 1-2 neuro-
toxic effects with no dose-limiting toxicities (DLTs). One patient experienced grade 3 
neurotoxicity prior to ipilimumab administration. Ten additional grade 3 toxicities were 
reported with gastrointestinal (n=5, 31%) 
as the most common. There were no 
grade 4/5 toxicities. Median PFS and OS, 
respectively, in Arm A were 2.5 months 
and 8 months, and in Arm B were 2.1 
months and not reached.
Conclusion: Concurrent ipilimumab 10 
mg/kg with SRS is safe. The WBRT arm 
was closed early due to slow accrual, but 
demonstrated safety with ipilimumab 3 
mg/kg. No patient experienced DLT. Larger 
studies with ipilimumab 10 mg/kg and SRS 
are warranted.
INTRODUCTION
Brain metastases (BM) occur in more 
than half of patients with advanced 
melanoma, and central nervous system 
disease burden often contributes to their 
death.1,2 The historic median survival 
of patients with BM from melanoma is 
4.7 months.3 Traditional BM treatment 
options includes surgery, whole brain 
radiation therapy (WBRT), and stereo-
tactic radiosurgery (SRS), and can prevent 
neurological decline and may also 
improve overall (OS).4-7 There has been 
increasing interest in radiotherapy (RT) 
combined with immunotherapy (IT) with 
growing evidence supporting a potential 
synergistic effect. It remains unclear the 
role that this synergism has on toxicity.8
Activated T-cells and antibodies targeting 
tumor-associated antigens (TAAs) 
detected in blood from cancer patients 
supports an active role for an anti-tumor 
immune response.9 T-cell infiltrates in 
melanoma have prognostic significance, 
and when identified within nodal metas-
tases, predict benefit in patients treated 
with neoadjuvant interferon-α-2b.10-13 
Cytotoxic T-lymphocyte-associated antigen 
4 (CTLA-4), is a negative regulator of 
T-cell-mediated anti-tumor immune 
responses and therefore represents a 
critical checkpoint, controlling both 
response duration and intensity.14-16 Ipili-
mumab (MDX-010, Bristol-Myers Squibb) 
is a fully human monoclonal antibody 
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Dose-Escalation Scheme
Ipilimumab was administered intrave-
nously over 90 minutes once every 3 
weeks for 4 total doses and was dose-
escalated independently in each arm 
with no intra-patient escalation. The FDA 
approved dose of 3 mg/kg was the starting 
dose. Rationale for ipilimumab dose esca-
lation to 10mg/kg was based on findings 
from the randomized, double-blind, 
phase 2 dose-ranging study of ipilim-
umab monotherapy demonstrating the 
best overall response rate in the 10 mg/
kg group (11.1%, 95% CI 4.9-10.7) versus 
the 3 mg/kg group (4.2%, 95% CI 0.9-11.7), 
suggesting further investigation of this 
higher dose.26 Following the initial 4 treat-
ments, maintenance dosing was offered 
to patients without unacceptable toxicity 
(refractory grade > 3 immune-related 
adverse events [irAEs]) at the same dose 
level given every 12 weeks until disease 
progression, toxicity requiring discontinu-
ation, or consent withdrawal.
Dose-Limiting Toxicity
Adverse events (AEs) were recorded with 
the Common Terminology Criteria for 
Adverse Events version 4.0 (CTCAE v.4). 
Dose-limiting toxicity (DLT) was defined 
as any grade 3 or higher treatment related 
toxicity occurring within 30 days of 
completing RT. Any neurological toxicity 
of grade 3, 4, or 5 was considered dose-
limiting (except symptoms present prior to 
study enrollment or expected sequelae of 
surgery or SRS). All patients were followed 
for AEs for 4 weeks following the last dose 
of ipilimumab. Intratumoral hemorrhage 
clinical trial was performed between 
October 2012 and August 2014, at 
Thomas Jefferson University and Ohio 
State University. All patients were over 18 
years old, Eastern Cooperative Oncology 
Group (ECOG) performance status 0 or 1, 
with normal hepatic and renal function 
and with histologic and radiographic 
confirmation of diagnosis. Blood count 
requirements were as follows: absolute 
neutrophil count ≥ 1000/µL, hemoglobin 
≥ 9g/dL, platelets ≥ 75,000/µL. Patients 
were excluded if they had a history of 
chronic infection (HIV or Hepatitis), 
autoimmune condition, abnormal 
thyroid function, or leptomeningeal 
carcinomatosis.
Radiotherapy
Patients were enrolled onto one of two 
arms depending on their IC disease 
burden. Arm A (WBRT) included patients 
with 5 or more BM, any lesion >4 cm 
maximal diameter, or 1 completely 
resected BM with postoperative cavity >4 
cm. Arm B (SRS) included patients with 
fewer than 5 BM (all ≤4 cm in diameter) 
or a single postoperative cavity <4 cm. 
Within each arm, RT dose was prede-
termined. WBRT dose was 30 Gy in 10 
fractions. Ipilimumab was administered 
on day 3 of RT in Arm A. Arm B patients 
received SRS according to the maximum 
diameter of the BM or resection cavity 
according to dose prescriptions in RTOG 
90-05.25 Ipilimumab was administered 
2 days following SRS in Arm B (Figure 1).
directed against the CTLA-4 receptor and 
is FDA approved for patients with unre-
sectable or metastatic melanoma.17,18,19 
One of the larger studies to investigate 
ipilimumab evaluated 127 patients and 
demonstrated an OS benefit (93 v. 42 
weeks, P=0.0028) for patients who 
received concomitant IT and RT.20 
Early in vitro studies showing a broad 
shoulder in the cell survival curves and a 
high repair rate in melanoma cells have 
inferred better tumor response with 
higher radiation doses.21,22 Moreover, SRS 
delivery in close proximity to IT yields the 
possibility of increased immunomodula-
tion which has been hypothesized to 
have an effect on distant control. This 
so-called “abscopal effect” is rare and 
intriguing, although specific mechanisms 
are currently incompletely under-
stood.23,24 In addition to the potential 
immunogenic advantages, concomitant 
treatment also limits delays in subsequent 
therapy.
To the best of our knowledge, we report 
the first prospective phase I study evalu-
ating concurrent ipilimumab with SRS or 
WBRT for patients with melanoma BM, 
assessing the safety and tolerability of 
concomitant therapy as well as intra-
cranial (IC) and extracranial (EC) control, 
progression-free survival (PFS), and OS.
MATERIALS AND METHODS
Study Design and Participants
This IRB-approved, open-label, phase I, 
Figure 1.  Treatment Schedule
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death or last patient contact (censored 
observation). Analysis of EC control, 
new BM development, and safety/toler-
ability was done separately for each arm. 
All subjects enrolled in the study who 
received at least one dose of ipilimumab 
were analyzed.
Role of the Funding Source
This study was funded by Bristol-Myers 
Squibb (New York City, NY) which 
provided the study drug and worked 
with the senior authors in the design 
and analysis. All authors jointly approved 
this work for submission and confirm 
the accuracy of the data. No additional 
authors not listed contributed to this 
work. All authors affirm that this trial 
was performed in accordance with the 
protocol and all amendments.
RESULTS
Patient Characteristics
Of the 26 patients screened for the trial, 
17 signed informed consent and were 
deemed eligible. One patient never 
received protocol therapy due to deterio-
rating health following consent. Sixteen 
patients received study therapy and were 
analyzed (Figure 2). Table 1 summarizes 
the patient and clinical characteristics, 
separately for the two arms. Overall, the 
mean age at time of BM diagnosis was 60 
(SD, 5-13) and 75% of the patients were 
male. There were 8 patients each with 
ECOG performance status of 0 and 1. 
Nine patients (56%) had initial BM surgery. 
Thirteen patients (81%) had EC metas-
tases at the time of BM diagnosis and 5 
(38%) received RT for their EC disease.
In Arm A (WBRT, n=5), the median 
number of lesions was 6 (range, 1 to >10) 
and the dose was 30 Gy in 10 fractions 
for all patients. In Arm B (SRS, n=11, the 
median number of lesions was 2 (range, 
1 to 3) and the median dose was 24 Gy 
(range, 15 to 24 Gy). In total, 20 lesions/
cavities were treated with SRS with a 
median planning target volume of 3.25 
cc per individual lesion (range, 0.1-22.7 
cc). The median per patient treatment 
volume was 8.5 cc (range 0.5-29.2 
cc). The median number of completed 
cycles of ipilimumab was as follows: 4 
(range, 2 - 4+14 maintenance) for dose 
level 3 mg/kg (n=7), and 3 (range, 2 - 4 
accrual of up to 12 patients for each arm, 
with up to 9 patients accrued from either 
Thomas Jefferson University or Ohio 
State University. Initially 3 patients were 
enrolled at the 3 mg/kg level. If none of 
these patients experienced a DLT, enroll-
ment continued to the 10 mg/kg level. 
If 1 of the 3 experienced toxicity at that 
level, 3 additional patients were accrued 
to the initial dose level. While waiting to 
complete the toxicity assessment for 
each triplet, additional patients could 
be accrued on the same dose, although 
their outcome was not considered for 
dose escalation purposes. No patient was 
treated at a higher dose until the 3 or 6 
patients completed their toxicity evalua-
tion period at the current dose. 
Data were analyzed separately for the 
two arms. Kaplan-Meier estimates for 
OS and PFS were computed in Stata 14 
(StataCorp, College Station, TX). PFS was 
analyzed from the date of SRS (or first day 
of WBRT) to the date of recurrence or 
progression. OS was analyzed from the 
date of first RT fraction to the date of 
was defined as new or worsening signs 
of bleeding within the irradiated tumor or 
cavity volume.
Assessment of Efficacy 
Contrast-enhanced MRI of the brain was 
performed at week 7 and then every 2 
months for 1 year, then every 3 months. 
All MRIs were interpreted using Response 
Evaluation Criteria In Solid Tumors 
(RECIST, version 1.1)27 and immune-
related response criteria (irRC).28 Overall 
response using irRC was classified as 
immune-related complete response 
(irCR), partial response (irPR), stable 
disease (irSD), or progressive disease 
(irPD) based on the predefined combi-
nation of parameters.28 For evaluation of 
EC disease, CT of the chest, abdomen, 
and pelvis was performed at week 7 and 
13 following enrollment, and every 3 
months subsequently.
Statistical Methodology
A two-stage 3+3 accrual design29 was 
used at each dose considered with goal 
Figure 2.  Consort Diagram
26 patients screened
9 screen failures
16 assigned 
treatment & analyzed
lpilimumab 
3 mg/kg
4 in analysis 
3 died; 1 alive
lpilimumab 
10 mg/kg
1 in analysis 
1 alive
lpilimumab 
10 mg/kg
8 in analysis 
21 died; 6 alive
17 deemed eligible 
and consented
1 patient never 
recieved study terapy 
due to deteriorating health
Arm A, WRBT 
n=5
Arm A, WRBT 
n=5
lpilimumab 
3 mg/kg
3 in analysis 
1 died; 2 alive
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maintenance) for dose level 10 mg/kg 
(n=9). Two patients in both arms received 
pre-treatment dexamethasone (mean 
dose 6 mg/day and 3.5 mg/day in the SRS 
and WBRT arms, respectively).
Toxicity
Ipilimumab in combination with RT 
was well tolerated. There were 21 
grade 1-2 neurotoxic effects including 
the following: headache (n=6, 37.5%), 
nausea/vomiting (n=3, 18.8%), subclinical 
intracranial hemorrhage (n=4, 25%), 
dizziness (n=1, 6.3%), vision changes 
(n=1, 6.3%), tinnitus/hearing loss (n=3, 
18.8%), facial palsy (n=1, 6.3%), weak-
ness/neuropathy (n=1, 6.3%), and seizure 
(n=1, 6.3%). There were no documented 
reports of pseudoprogression in our 
small sample of patients.
One patient experienced headache 
prompting emergency room evaluation, 
categorized as a grade 3 neurotoxic 
event. This toxicity occurred following 
SRS but prior to first IT administration 
and was therefore not considered a 
dose-limiting toxicity (DLT), but rather, 
an effect of surgery and SRS. The patient 
went on to receive 4 doses of ipilim-
umab plus one maintenance cycle prior 
to disease progression. There were no 
additional grade 3 neurotoxicities.
Table 2 summarizes the AEs in detail. 
In addition to the neurotoxicity above, 
there were 10 additional grade 3 toxici-
ties, including gastrointestinal most 
commonly (n=5, 31%). There were 
no grade 4 or 5 toxicities. Of note, no 
patients experienced radionecrosis.
Progression-Free Survival and 
Overall Survival
Median follow-up time was 8.0 months 
in Arm A (range, 3.5 to 24.1) and 10.5 
months in Arm B (range, 1.8 to 36.8) from 
first day of RT to last follow-up or death. 
At time of analysis, no patients were 
still on treatment. Fourteen patients in 
total progressed and/or died during the 
study’s follow-up (5/5 = 100% in Arm 
A and 9/11 = 82% in Arm B). Thirteen 
patients had IC progression (including 
the 6 who subsequently died). Median 
time to IC progression was 2.53 months 
(WBRT, range 0.3-18) versus 2.45 months 
(SRS, range 1-37). Overall response 
intracranially as defined by the irRC (15 
Figure 3.  Progression-free survival for the SRS and WBRT patients
	
	
Table 1.  Baseline Patient, Lesion, and Treatment Characteristics
Characteristic Value
Patients (n=16)
Mean age at IC diagnosis (range) 60 (37-75)
Sex, No. (%) Male 13 (81%)
Female 3 (19%)
ECOG performance status (n) 0 8
1 7
2 1
Number with extracranial metastases 13 (81%)
Number with pre-RT surgery 8 (50%)
Radiation technique WBRT 5 (31%)
Median # lesions (range) 6 (1->10)
SRS 11 (19%)
Median # lesions (range) 2 (1-3)
Median dose, Gy (range) 24 (15-24)
Ipilimumab Dose 3 mg/kg 9
Median # cycles completed (range) 4 (2-4+14 mainte-
nance)
Dose 10 mg/kg 7
Median # cycles completed (range) 3 (2-4)
Median length of follow-up after RT, months (range) 9.1 (2-37)
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with treatment sites as follows: lung (n=2), 
thoracic/lumbar vertebrae and lower 
leg soft tissue metastasis (n=1). Of the 3 
patients with no EC disease at the time of 
BM diagnosis, all 3 remained without EC 
disease at 2 month follow-up. Overall, 6 
patients experienced EC progression at 
2 months, 5 patients had stable disease, 
3 patients continued with no EC disease, 
1 patient had a partial response (after 
having her EC disease treated), and 1 
patient did not receive systemic imaging 
at the 2 month time point.
Seven patients developed new BM (as 
differentiated from previously treated BM) 
on follow-up imaging (Arm A, n=1 and Arm 
B, n=6) with the median time from first RT 
fraction to new BM diagnosis of 1.9 months 
(range, 0.97 to 8.2). The median time from 
first RT fraction to development of new BM 
in the one patient having received WBRT 
was 8.2 months.
DISCUSSION
To the best of our knowledge, we report 
the first prospective phase I study evalu-
ating concurrent ipilimumab with SRS or 
WBRT for patients with melanoma BM. 
The toxicity profile of escalating doses 
of ipilimumab demonstrated no grade 
4/5 toxicity, radionecrosis, or DLTs. Ipili-
mumab 10 mg/kg with SRS is safe and we 
recommend this dose for further study 
with concurrent SRS. Additional phase I 
studies will be necessary to determine 
the safety of WBRT with ipilimumab 10 
mg/kg, as we had to terminate this part 
of the trial due to slow accrual, however 
safety was demonstrated with concur-
rent WBRT and ipilimumab 3 mg/kg.
CA184-04230 was a phase II trial that 
evaluated ipilimumab in patients with 
melanoma BM. Patients were specifically 
excluded from the trial if they received 
any RT within 14 days of ipilimumab 
and only 8% of patients had received 
prior SRS.  There were no unexpected 
toxicities and activity was demonstrated 
particularly when BM were small and 
asymptomatic.30 However, this trial does 
not specifically evaluate the safety of 
concurrent RT and ipilimumab.
Hodi et al18 reported a large study evalu-
ating 676 patients randomized to receive 
ipilimumab 3 mg/kg in combination 
with an investigational peptide vaccine 
= 60% in Arm A and 3/11 = 27% in Arm 
B). Cause of death for these patients was 
as follows: urosepsis (n=1), cardiac arrest 
(n=1), hemorrhagic progression of BM 
(n=2), IC progression (n=1), EC progres-
sion (small bowel rupture secondary to 
tumor, n=1).
Median OS was 8 months in Arm A and 
not reached in Arm B (Figure 4).
Of the 13 patients with EC metastases 
at the time of BM diagnosis, 3 patients 
received targeted RT to the EC disease 
evaluable patients) was a follows: irSD 
(n= 5, 33%), irPD (n=9, 60%), irPR (n=1, 
7%). Following SRS, of the patients who 
experienced new BM or progression of 
existing BM (n=8), salvage treatment was 
as follows: 4 received salvage WBRT, 3 
received further SRS, and one patient 
received no further IC treatment. All 
patients who failed following WBRT 
received SRS as salvage.
Median PFS time was 2.5 months in Arm 
A and 2.1 months in Arm B (Figure 3). 
Six patients died during follow-up (3/5 
Table 2.  Adverse effects in SRS (n=11) and WBRT (n=5) arms
Grade 1 – 2 Grade 3 Grade 4
SRS WBRT SRS WBRT SRS WBRT
Headache 4 2 1 0 0 0
Post-treatment subclinical intracranial 
hemorrhage
4 0 0 0 0 0
Nausea, vomiting, abdominal pain 2 1 0 0 0 0
Fatigue 1 1 0 1 0 0
Hearing loss, otitis, tinnitus 1 2 0 0 0 0
Skin reaction, pruritis 2 3 0 0 0 0
Diarrhea 3 2 4 1 0 0
Insomnia 0 1 0 0 0 0
Anorexia 1 2 0 0 0 0
Hot flashes 0 1 0 0 0 0
Constipation 0 1 0 0 0 0
Lymphopenia 1 0 0 1 0 0
Visual changes 0 1 0 0 0 0
Hypophysitis 0 0 0 1 0 0
Hypertension 0 1 0 0 0 0
Alopecia 0 2 0 0 0 0
Dizziness 0 1 0 0 0 0
Bone pain 0 1 0 0 0 0
Anemia 1 1 1 0 0 0
Thrombocyopenia 1 0 0 0 0 0
Depression 1 0 0 0 0 0
Lipase increase 1 0 0 0 0 0
Weakness, neuropathy 1 0 0 0 0 0
Seizure 1 0 0 0 0 0
Facial palsy 1 0 0 0 0 0
Pleuritic pain, effusion 1 0 0 0 0 0
Abbreviations: SRS=stereotactic radiosurgery; WBRT=whole brain radiation therapy.
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Seven of the 13 patients treated concur-
rently had documented hemorrhage 
partially accounting for the enlarge-
ment and 2 lesions had documented 
recurrence. Of note, the IT was not 
standardized in this retrospective review 
and included ipilimumab, nivolumab, 
and pembrolizumab.32
Kiess et al.33 retrospectively reported 
response and toxicity on 46 patients with 
melanoma BM who received ipilimumab 
(3 mg/kg or 10 mg/kg) with SRS (median 
dose 21 Gy) between 2005 and 2011. 
Patients treated with SRS either before 
or during ipilimumab had improved OS 
compared to those having SRS afterward 
(1-year OS 56% vs 65% vs 40%, p=0.008). 
Moreover, only approximately 20% of 
patients experienced grade 3 or 4 toxicities. 
Interestingly, SRS before or during IT was 
more likely to be associated with a tempo-
rary increase in size or hemorrhage of the 
irradiated lesion, likely secondary to inflam-
mation, and asymptomatic in the majority 
of cases.33 Most likely due to the small 
numbers in our study and the frequency 
of neurosurgical intervention prior to SRS 
(6/11 patients, 55%), we did not observe the 
same temporary lesional edema following 
combination therapy. Similarly, no lesions 
were deemed to undergo pseudoprogres-
sion following SRS.
When evaluating the effects of IT, EC 
disease control is also of interest. First 
described in the 1950s, the abscopal 
effect refers to the seldom-reported 
phenomenon of tumor regression of a 
secondary site following RT to a sepa-
rate primary site.34 Seromic analysis and 
immunologic correlates of the abscopal 
effect in a patient with melanoma has 
demonstrated antigenic targets with 
increased antibody responses following 
RT.35 The surprising response achieved 
by the patient in this report provided new 
insight in the mechanisms of combina-
tion therapy. Our study evaluated EC 
control as a secondary endpoint with 
a similar hypothesis that IT delivered in 
close proximity to SRS may impact distant 
control. In our study, we did not observe 
the abscopal effect extracranially or intra-
cranially at non-target sites. 
Limitations of our study include slow 
accrual to Arm A, leading to its early closure. 
This arm did show safety with ipilimumab 3 
mg/kg, however. An additional caveat to 
and a 1-year OS of 65% versus 30% 
(p<0.0001).31
In terms post-RT lesion size, reports with 
combined therapy have been conflicting. 
Qian et al.8 recently reported results 
regarding 313 melanoma BMs in 53 
patients treated concurrently (defined 
as RT and IT delivery within 4 weeks 
of each other).8 IT was as follows: 54 
patients (72%) received anti-CTLA-4 
and 21 patients (28%) received anti-
PD-1. No patients received combination 
IT. The median percent reduction in 
lesion volume was significantly greater 
for the concurrent group. The timing 
of IT and SRS did not appear to effect 
post-treatment lesion size.8 In this 
report, only 39 lesions in 24 patients 
demonstrated regrowth to >120% base-
line volume. Authors concluded that the 
early response is greater and more rapid 
with concurrent therapy. There was not 
specific mention of tumor hemorrhage 
in this study.8 In contrast to this report, 
preliminary data reported by Shen et al. 
showed an increase in lesion size in 13 of 
26 lesions treated concurrently (defined 
as IT starting “prior to or with SRS”).32 
Lesion enlargement in the SRS alone 
cohort occurred with similar frequency. 
(gp100), ipilimumab alone, or gp100 
alone. OS was 10.0 months in patients 
receiving ipilimumab plus gp100, 
compared to 10.1 months in the ipilim-
umab alone arm and 6.4 months in the 
gp100 alone arm (p<0.001). Eighty-two 
patients (12.1%) had CNS disease in this 
study.18  This data is comparable to our 
study with the median OS not reached 
in the SRS arm and 8 months in the 
WBRT arm (median follow-up 10.5 and 
8 months, respectively). Given that OS 
has not been reached in the SRS arm 
of our trial, we hypothesize that the 
timing of ipilimumab in close proximity 
to SRS may mechanistically promote 
duration and intensity of response in 
these patients, although this study is 
hypothesis-generating in that regard.
To this end, a recent report by Johnson 
et al.31 demonstrated the impact of 
systemic agents on the clinical outcomes 
of patients with BM. Although this review 
included patients with many primary 
tumor types, and a variety of agents 
(BRAF inhibitors, ipilimumab in patients 
with melanoma primaries), the authors 
did show that patients receiving IT 
with SRS compared to SRS alone had a 
median survival of 18 versus 7 months 
Figure 4.  Overall survival for the SRS and WBRT patients
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development was 10.2 months (range, 
2.8-22.1 months), which is slightly shorter 
than the median follow-up in our SRS 
arm.40 Therefore, although our study 
does have relatively short follow-up, it is 
worthwhile to demonstrate that we have 
no documented cases of radionecrosis.
In an era where combined modality 
targeted therapy is becoming more 
promising and increasingly utilized, it is 
important to establish the safety profiles 
of these modalities.41 Our results demon-
strate the safety of combining SRS with 
either ipilimumab 3 mg/kg or 10 mg/kg. 
Future exploration of multi-agent immu-
notherapy in combination with SRS for 
melanoma BM is warranted, although 
currently there are no clinical trials open 
to accrual evaluating the safety and effi-
cacy of this combination of treatment.
therapy or pembrolizumab alone.
An additional limitation is the relatively 
short follow-up possibly limiting the 
capture of late toxicity. The median 
follow-up in the arm receiving SRS was 
10.5 months which may be long enough 
to catch some, but not all cases of radio-
necrosis. A recent report by Colaco et 
al.40 evaluating 180 patients with BM who 
received radiosurgery with either cyto-
toxic chemotherapy, targeted therapy, 
or IT noted a significantly increased rate 
of radionecrosis or treatment-related 
imaging changes in the IT group (OR 
2.40 [95% CI 1.06–5.44]; p = 0.03).40 The 
median follow-up was 11.7 months and 
31% of patients had melanoma primaries. 
Of importance, 30% of patients received 
prior WBRT which increases one’s risk 
for subsequent radionecrosis following 
radiosurgery. For patients who received 
IT alone, median time to radionecrosis 
our study is that ipilimumab alone is no 
longer the standard of care for previously 
untreated advanced melanoma. First-line 
therapy is now either anti-programmed 
death 1 (PD-1) inhibitor monotherapy 
(pembrolizumab or nivolumab) or a 
combination of nivolumab with ipilim-
umab.36 This combination of therapies 
improved overall response rate and 
PFS as compared with either treatment 
alone, however, demonstrated signifi-
cantly increased toxicity. Compared 
to single agent therapy, the effect of 
combination therapy on OS has not yet 
been demonstrated.37,38 Pembrolizumab 
alone demonstrated prolonged PFS and 
OS and had less high-grade toxicity as 
compared to ipilimumab in patients with 
advanced melanoma as demonstrated in 
the KEYNOTE-006 trial.39 Based on these 
results, future studies will need to address 
RT with combination checkpoint inhibitor 
Table 3.  Previously reported series of melanoma brain metastases treated with immunotherapy.
Primary 
author
Year Analysis type Primary Patients 
who got 
SRS (n)
IT agent/timing Patients 
receiving IT 
and SRS (%)
Median 
survival 
(months)
OS Other
Knisely41 2012 Prospectively 
collected, 
retrospectively 
melanoma 7 Ipilimumab (SRS first, 
n=16; IT first, n=11)
27 (35%) 21.3 (with IT) 
v. 4.9 (no IT)
2 year: 47.2% 
(with IT) v. 
19.7% (no IT) 
p=0.044
Grade ≥3 
toxicity NR
Johnson3 2015 retrospective renal cell, 
melanoma, 
breast, colon, 
esophagus, 
lung
737 various agents 
(including BRAF 
inhibitors & 
ipilimumab), IT 
concurrently or within 
30 days of SRS
167 (23%) 18 (with IT) 
v. 7 (no IT)
1 year: 65% 
(with IT) v. 
30% (no IT) 
p<0.0001
Grade ≥3 
toxicity NR
Kiess3 2015 retrospective melanoma 46 Ipilimumab (concur-
rent, n=15; SRS first, 
n=19; IT first, n=12)
46 (100%) 12.4 
(all patients)
1 year: 65% 
(concurrent) 
v. 56% (SRS 
before)  v. 40% 
(IT before)
P=0.008
1 year 
RR: 69% 
(concurrent) 
v. 64% (SRS 
before)  v. 
92% (IT 
before)
P=0.003
Patel42 2015 retrospective melanoma 54 Ipilimumab (within 4 
months of SRS)
20 (37%) 9.1 (with IT) v. 
8.0 (no IT) 
p=0.84
NA 1 year LC: 
71.4% (with 
IT) v. 92.3% 
(no IT)
p=0.40
NR: not reported; IT: immunotherapy; RR: regional recurrence
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Principles of Pituitary Surgery
INTRODUCTION
Evolution of Transsphenoidal Surgery
Since the initial description of a transnasal approach for the treatment of pituitary 
tumors in 1907, transsphenoidal surgery has undergone a continuous evolution marked 
by close collaboration between neurosurgeons and otolaryngologists. Oskar Hirsch, 
developed a lateral endonasal approach in 1910 that he initially performed as a five step 
procedure over a several week period before simplifying the procedure to a single-
step submucosal transseptal approach.1 Contemporaneously, Harvey Cushing began 
approaching pituitary tumors using a transsphenoidal approach but transitioned to the 
transcranial route due to his concern that an endonasal approach provided restricted 
access and poor illumination, compromising adequate decompression of the optic 
apparatus.2 Most neurosurgeons followed Cushing’s lead and transsphenoidal surgery 
was not “rediscovered” until Jules Hardy introduced the surgical microscope in the 
1960s.3
The first completely endoscopic transsphenoidal approach for pituitary tumors was 
reported in 1992 by Jankowski and further advanced by the collaborative teams of 
Jho and Carrau in Pittsburgh and Sethi and Pillay in Singapore.4,5 Over the last 20 
years, the endoscopic technique has been adopted by a multitude of surgeons who 
have favored the dynamic panoramic view afforded by the endoscope, allowing for 
improved visualization and better resection of tumors extending into the suprasellar 
area and cavernous sinuses. Additionally, the advent of extended endoscopic endonasal 
approaches, such as the trans-planum and lateral trans-cavernous, has facilitated resec-
tion of large, invasive pituitary tumors that were previously deemed unresectable or 
requiring transcranial surgery. 
Critics of the endoscopic approach have 
rightfully focused on the loss of stereo-
scopic vision as a major limitation with 
mastery of the procedure demanding a 
steep learning curve. Prospective studies 
directly comparing the microscopic 
and endoscopic approaches for pitu-
itary tumors have not been performed, 
however, an increasing body of literature 
has established the safety and non-inferi-
ority of endoscopic endonasal techniques 
and several studies have demonstrated 
improvement in the extent of tumor 
resection. McLaughlin et al. reported 
that following microsurgical resection of 
pituitary adenomas, endoscopy revealed 
residual tumor leading to further resec-
tion in 36% of cases.6 Messerer et al. 
found their gross total resection rate 
increased from 50% utilizing the micro-
scope to 76% upon initial conversion to 
the endoscopic approach.7 In this review, 
we describe the principles of pituitary 
surgery including the key-elements of 
surgical decision-making and discuss 
the technical nuances distinguishing 
the endoscopic from the microscopic 
approach.
PRINCIPLES OF SURGERY
Indications for Surgery
Pituitary adenomas are most frequently 
categorized as functional or non-
functional depending on their hormonal 
secretory pattern. Prolactinomas repre-
sent the most common functional 
adenoma and the mainstay of treatment 
is dopamine-agonist medical therapy, 
with surgical treatment reserved for 
patients who fail to respond despite 
dose-escalation or are intolerant to the 
medications. Transsphenoidal surgery 
remains the primary treatment for 
adenomas secreting ACTH (Cushing’s 
disease) and growth-hormone (acro-
megaly) with biochemical remission rates 
significantly correlated with tumor size 
and invasiveness.7 
Non-functional pituitary adenomas 
(NFPA) are extremely common — 
autopsy and radiographic studies reveal 
the presence of NFPA in 11-27% of the 
Figure 1.  Nasal stage.
A. “1.5” approach to the sphenoid sinus with wide ipsilateral sphenoidotomy and limited 
contralateral sphenoidotomy with preservation of inferiorly located sphenopalatine arte-
rial supply to the nasoseptal flap. B. “Tunnel” approach for patients with septal spurs with 
ipsilateral wide sphenoidotomy and submucosal elevation of septal mucoperichondrium.
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tumor resection with co-registration of 
the preoperative CT and MR images using 
facemask fiducials. Although neuronavi-
gation is valuable, over-reliance on this 
adjunct and a failure to correlate with 
anatomic landmarks can lead the surgeon 
off course. The head is slightly elevated to 
reduce mucosal congestion and venous 
oozing/bleeding during the approach. 
We do not routinely prepare the skin of 
the face or nasal cavity with antiseptic 
solution, but graft sites such as the lateral 
thigh for fascia lata or adipose tissue 
should be prepared in a sterile standard 
fashion. 
The turbinates are gently lateralized with a 
blunt instrument. Although routine resec-
tion of the middle turbinates is favored 
by some surgeons to increase the nasal 
working corridor, we have found that 
turbinate lateralization combined with 
a limited posterior septectomy provides 
more than sufficient access to the sella 
for pituitary tumor resection and mini-
mizes post-operative patient sinonasal 
morbidity.13,14 A binarial approach is typi-
cally performed allowing for two surgeons 
to work simultaneously with up to four 
instruments in the field, including the 
endoscope. In our experience, a pedicled 
nasoseptal flap (NSF) is rarely necessary 
for cranial base repair during standard 
transsellar pituitary adenoma resection, 
however, in certain cases the need for 
a NSF is unanticipated or may become 
necessary during future surgeries.15 As 
such, we advocate at least unilateral pres-
ervation of the NSF whenever possible 
and have described a variety of tailored 
approaches to the sphenoid sinus that 
enable NSF preservation applicable to 
endoscopic pituitary surgery. Our stan-
dard approach, termed the “1.5 approach”, 
involves an ipsilateral wide sphenoid-
otomy (“1”) on the working instrument 
side with a limited contralateral sphe-
noidotomy (“0.5”) on the endoscope side 
(Figure 1A). The limited sphenoidotomy 
is performed by extending the natural 
sphenoid os superiorly with Kerrison 
rongeurs, thus preserving the more 
inferiorly located sphenopalatine artery 
supply to the nasal septal mucoperios-
teum and mucoperichondrium. Addition 
of a limited posterior septectomy (typi-
cally 1cm) allows communication of the 
binarial sphenoid exposures and provides 
ample working room and maneuverability 
later should it prove necessary. Addi-
tionally, detection of the position of the 
normal compressed pituitary gland on 
the pre-operative MRI assists with the 
preservation of hormonal function as 
intraoperative distinction of the gland 
from tumor based on color and consis-
tency differences is frequently subtle.
Computed tomography studies provide 
complementary information helpful in 
surgical planning. Coronal and sagittal 
reconstructions reveal bony changes 
such as erosion of the sellar floor and 
dorsum and can be used intraoperatively 
for image guidance, especially in patients 
with altered sinonasal anatomy related 
to prior surgery. Similarly, we have found 
preoperative nasal endoscopy helpful 
to optimize our surgical plan and avoid 
complications related to paranasal sinus 
disease or anatomic variability. Typically, 
chronic rhinosinusitis does not represent 
an absolute contraindication to trans-
sphenoidal surgery, however, patients 
with acute rhinosinusitis, especially those 
with fungal disease, should be treated 
appropriately prior to elective surgery.11 
Otolaryngology preoperative evaluation 
is critical in patients with acromegaly 
who frequently present challenges for 
airway management during surgery due 
to soft tissue hypertrophy and bony 
abnormalities.12
Surgical Approach: Nasal Stage
The endoscopic surgical approach for 
pituitary tumors can be divided into the 
nasal, sphenoidal, and sellar stages. Since 
the inception of our endoscopic skull base 
program at Thomas Jefferson University 
in 2005, we have advocated for a team 
approach between otolaryngology and 
neurosurgery. The complementary skill of 
experienced sinus and pituitary surgeons 
has enabled us to optimize oncologic 
outcomes and minimize complications, 
both minor and major. Our approach to 
pituitary surgery has evolved and we have 
adopted a tailored approach to these 
tumors based on their size, invasive-
ness, and secretory pattern allowing us 
to minimize sinonasal disruption without 
compromising tumor resection.
Patients are positioned supine with the 
head on a gel headrest. Neuronavigation 
is used routinely to help guide the surgical 
approach and assess the adequacy of 
population (8,9). While most NFPA are 
microadenomas (<1cm) and clinically 
asymptomatic, macroadenomas may 
present with compressive symptoms 
including headache, visual impairment, 
hormonal insufficiency, and cranial nerve 
palsies due to cavernous sinus exten-
sion. Surgery is generally indicated for 
patients with macroadenomas causing 
visual compromise or exhibiting growth 
on serial imaging studies. Approximately 
5% of patients with pituitary adenomas 
present with apoplexy due to intratumoral 
hemorrhage or infarction.10 
Preoperative Surgical Planning
The main goal in endoscopic pituitary 
surgery is to maximize tumor resection 
while avoiding complications such as 
visual deterioration, cerebrospinal fluid 
(CSF) leakage, endocrinopathy, vascular 
injury, and sinonasal morbidity. Although 
pituitary adenomas are typically benign 
lesions, recurrences are common 
following incomplete surgical removal 
and thorough preoperative surgical 
planning is essential to achieve optimal 
outcomes. 
Magnetic resonance imaging (MRI) 
studies reliably delineate the size and 
extension of pituitary tumors, with the 
notable exception of some ACTH-
secreting microadenomas that may be 
radiographically occult. Inspection of 
the preoperative MRI provides an assess-
ment of the likelihood of gross total 
resection primarily based on cavernous 
sinus extension as well as a prediction 
of the surgical challenges that will be 
encountered such as intraoperative CSF 
leakage and a narrow surgical corridor 
due to reduced distance between the 
parasellar carotid arteries. Large tumors 
that extend vertically within the supra-
sellar area may significantly compromise 
the diaphragma sellae or even invade 
the ventricular system resulting in high-
flow CSF leaks requiring more extensive 
repairs such as nasoseptal flap (NSF) 
placement, lumbar drainage, or use of 
autologous tissues (e.g., fascia lata or 
adipose tissue). As discussed in more 
detail later, preoperative anticipation 
of the need for a NSF is critical as the 
flap must either be harvested during the 
initial nasal stage of the approach or the 
vascular pedicle to the flap preserved 
such that a viable flap can be harvested 
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rotatable Kerrison rongeurs after a pilot 
bony opening has been created with the 
drill or Cottle elevator. As opposed to the 
microscopic approach where all but the 
central portion of the intrasellar tumor is 
removed based on “feel”, bony removal 
for the endoscopic approach needs to be 
more extensive to maximize the visualiza-
tion benefits of the endoscope and allow 
for tumor dissection. In the endoscopic 
approach, the anterior wall of the sella 
should be removed to the medial edges 
of the cavernous sinuses bilaterally and 
extended superiorly to the intracavernous 
sinus in the region of the tuberculum sella 
(Figure 2A). The amount of bony removal 
of the sellar floor is variable, however, 
for tumors with significant suprasellar 
extension additional removal of the floor 
allows for introduction of more vertically 
angled instruments helpful in removing 
tumor that fails to descend into the sella 
following debulking. For tumors that 
clearly invade the cavernous sinuses, 
further lateral bony removal across the 
anterior face of the parasellar carotid 
arteries can be performed.
Surgical Approach: Sellar Stage
The exposed dura of the sella is then 
opened in a cruciate fashion with a 
retractable knife and angled scissors. 
Horizontal cuts should be made in a 
lateral-to-medial direction to avoid carotid 
injury while the vertical incision should 
be made in a superior-to-inferior direc-
tion to avoid inadvertent entry into the 
anterior arachnoid cistern with resultant 
CSF leakage (Figure 2A). The principles 
of tumor removal differ for micro- and 
macro-adenomas. Historically, pituitary 
adenomas have been resected in a piece-
meal fashion using a variety of blunt ring 
curette-type instruments. Oldfield et al., 
however, demonstrated the advantages of 
dissection of the histologic pseudocapsule 
surrounding pituitary adenomas, allowing 
microadenomas to ideally be resected in 
an en-bloc extracapsular fashion (Figure 
2B).19 When feasible, en bloc resection 
reduces the likelihood of tumor remnants 
and increases biochemical remission for 
functional adenomas.20 Rarely, in patients 
with Cushing’s disease, a pituitary micro-
adenoma may not be visible on MR 
imaging but the diagnosis confirmed by 
adrenocorticotropic hormone (ACTH)-
dependent elevation of cortisol levels and 
Surgical Approach: Sphenoid Stage
The anatomy of the sphenoid sinus is 
highly variable in regard to its bony septa 
and pneumatization. The configuration 
of sphenoid sinus pneumatization can 
significantly affect access to the sella. 
The pneumatization of the sphenoid 
sinus is usually completed by age ten and 
the majority of adults possess the well-
pneumatized sellar pattern.18 The sellar 
floor lies along the posterior wall of the 
sphenoid sinus within the midline and 
the importance of maintaining a midline 
orientation cannot be overstated. In addi-
tion to the sellar prominence, anatomic 
landmarks along the posterior sphenoid 
wall include the medial and lateral opti-
cocarotid recesses, parasellar carotid 
prominences, and clival recess. Frequently, 
the entirety of these landmarks may not 
be plainly apparent and careful attention 
to the preoperative imaging combined 
with judicious use of neuronavigation will 
prevent inadvertent complications. The 
intra-sphenoidal septa should be taken 
down with use of the high-speed drill or 
Thru-cutting instruments, avoiding any 
fracturing or rotational maneuvers as 
these septa often have posterior attach-
ments along the carotid prominences. 
Additionally, anticipating the presence 
of Onodi air cells will prevent injury to 
the optic nerves. Endoscopic trans-
sphenoidal pituitary approaches can be 
safely performed in children and adults 
with the conchal and pre-sellar variant 
patterns, but prolonged drilling will be 
required along with an increased reliance 
on neuronavigation. 
The sella is typically expanded in the 
presence of macroadenomas and the 
bony floor may be thinned or absent. 
Conversely, microadenomas do not 
cause expansion or thinning of the sellar 
floor, often requiring bone removal with 
a diamond burr to access the dura. The 
sphenoid mucosa should be stripped 
from the sellar floor bluntly or with 
gentle bipolar cautery prior to drilling 
the sella. Monopolar cautery may lead 
to optic nerve or carotid injury and its 
use is highly contraindicated along the 
posterior sphenoid wall. If a NSF will be 
placed for repair, further mucosal stripping 
should be performed to prevent delayed 
mucocele development by trapping 
mucosa under the flap. Bony removal of 
the sellar floor is usually performed with 
(unpublished data). In patients with nasal 
obstruction due to septal deviation 
or large spurs, a “tunnel approach” is 
performed involving a septoplasty and 
submucosal “tunnel” with a wide contra-
lateral sphenoidotomy (Figure 1B). The 
approach begins with a standard hemi-
transfixion incision used for septoplasty 
and the septal mucoperichondrium is 
raised and extended posteriorly over the 
vomer and laterally along the sphenoid 
rostrum. A septoplasty or spur removal is 
then performed, with the resultant unilat-
eral “tunnel” analogous to the standard 
microscopic transeptal approach with 
preservation of the NSF ipsilaterally. On 
the contralateral side, a wide sphenoid-
otomy is performed. If NSF harvest proves 
necessary, the superior and inferior inci-
sions for the flap can be performed and 
elevation completed on the “tunnel” side. 
The NSF harvest and replacement (“raise 
and return”) approach involves a stan-
dard harvest of the NSF combined with 
a wide contralateral sphenoidotomy. We 
typically reserve this approach for cases 
in which there is a high likelihood of 
NSF utilization such as tumors with very 
significant vertical suprasellar extension 
or that extend anteriorly over the planum 
where, depending on tumor consistency, 
an extended endonasal approach may 
become necessary for complete tumor 
resection. This approach is also used 
for cases with potential for a high-flow 
CSF leak. If cranial base repair with the 
NSF proves unnecessary, the flap can 
be returned to its native position along 
the septum. These “raised and returned” 
flaps tend to heal quite well with minimal 
crusting and post-operative discomfort. 
We do not advocate routine harvest 
of the NSF, however, as this technique 
is associated with increased sinonasal 
morbidity including the possibility of 
olfactory dysfunction, septal perforation, 
and sensory loss due to superior alveolar 
nerve injury. A variety of authors have 
described “rescue flap” modifications 
where the nasoseptal flap is partially 
raised during the nasal stage such that the 
vascular pedicle is preserved, although 
these modifications have been associ-
ated in some cases with increased risk of 
olfactory loss.16,17
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System, NICO corp.) extremely helpful in 
performing tumor debulking with loca-
tion of the carotid arteries repetitively 
confirmed with neuronavigation and 
the micro-Doppler. In rare cases where 
adequate decompression cannot be 
safely performed through a standard 
transsphenoidal transsellar opening, 
we convert to an extended endoscopic 
approach (EEA) with drilling of the tuber-
culum sella and planum. The additional 
bony removal and more anterior dural 
opening enables tumor to be dissected 
from the optic nerves and chiasm under 
direct visualization but requires more 
extensive skull base repair. 
The most frequent areas of tumor 
residual following transsphenoidal resec-
tion of pituitary macroadenomas are 
the cavernous sinuses and suprasellar 
area.21 Once tumor resection is felt to 
be completed, the sellar cavity is directly 
inspected with 30-70° endoscopes, 
with careful attention to these areas as 
well as for detection of tumor remnants 
adherent to the normal pituitary gland. 
often leads to compromise and intraoper-
ative CSF leakage. To avoid this, the lateral 
superior recesses should be debulked 
prior to continued midline debulking. 
Once the tumor has been adequately 
debulked, the interface between the dura 
and the tumor pseudocapsule is defined 
with angled curettes and developed 
in an extracapsular fashion toward the 
medial cavernous sinus wall. For tumors 
without true cavernous sinus invasion, 
this pseudocapsule can be dissected 
circumferentially and then brought down 
away from the diaphragm. The transition 
zone between the normal gland and the 
tumor must be anticipated and carefully 
developed to avoid injury to the gland 
and resultant pituitary insufficiency. 
Infrequently, pituitary macroadenomas 
may be extremely fibrous and resection 
of these tumors can be considerably 
more dangerous due to the need for 
sharp debulking, placing the carotid 
arteries and optic apparatus at increased 
risk for injury. We have found use of 
ultrasonic aspirators and side-cutting 
rotatable microdebriders (NICO Myriad 
high-dose dexamethasone suppression. 
In these cases, ACTH levels are measured 
from the inferior petrosal sinuses using 
invasive catheters to determine the likely 
side of the adenoma within the sella. The 
pituitary gland is then explored system-
atically using a series of horizontal and 
vertical incisions to identify the adenoma 
beginning on the presumptive side 
(Figure 2C).
En bloc resection of macroadenomas is 
rarely possible and we advocate a strategy 
of systematic internal debulking followed 
by extracapsular dissection along the 
cavernous sinus walls and diaphragm. As 
shown in Figure 3, the inferior aspect of the 
tumor is first debulked with ring curettes 
in the midline before extending posteriorly 
to the dorsum sella and laterally toward 
the medial cavernous sinus walls. Pituitary 
adenomas are frequently soft tumors and 
overzealous interior debulking can lead to 
premature diaphragma sellae herniation 
with subsequent trapping of tumor within 
the folds of the collapsed arachnoid. 
Manipulation of the diaphragm in order to 
complete tumor removal from these folds 
Figure 2.  Microadenoma removal. 
A. Bony removal of sellar floor to medial extent of cavernous sinuses bilateral and 
cruciate dural opening performed with retractable blade. B. En bloc resection of pituitary 
microadenoma with extracapsular dissection. C. Pituitary gland exploration for occult 
microadenoma with staged vertical and horizontal gland incisions.
Figure 3.  Macroadenoma removal.
A. Initial debulking with blunt ring 
curettes is performed within the midline 
inferior extent of the pituitary macroad-
enoma. B. After interior debulking, 
extracapsular dissection of the lateral 
aspect of tumor is performed with sepa-
ration of the tumor pseudocapsule from 
the medial wall of the cavernous sinus. 
C. Superior extracapsular dissection of 
the tumor away from the diaphragma 
sellae. D. Symmetric descent of the 
diaphragm after complete macroad-
enoma removal.
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Cavernous Sinus Invasion
The cavernous sinuses are paired thin-
walled venous channels located lateral to 
the sella. The internal carotid artery (ICA) 
and its branches course within the center 
of the channel with the oculomotor, 
trochlear, abducens, and trigeminal 
cranial nerves located more laterally. 
Pituitary adenomas commonly invade 
the medial wall of the cavernous sinus 
within the carotid siphon with the extent 
of invasion predicting the likelihood of 
gross total tumor resection. Although 
the endoscopic approach provides 
improved visualization of tumor within 
the cavernous sinus, complete resection 
remains challenging.23 In the majority 
of patients, the presence of residual 
benign adenoma within the cavernous 
sinuses can be managed expectantly or 
with radiation therapy (e.g., stereotactic 
radiosurgery or stereotactic radiotherapy) 
with control rates for non-functional 
tumors typically around 90%.24 Tumor 
control rates following radiosurgery 
are significantly reduced, however, for 
larger volume tumors demonstrating the 
importance of maximal surgical debulking 
prior to radiation treatment. Biochemical 
remission rates for functional adenomas 
are significantly lower than tumor control 
rates with remission achieved in only 
approximately half of patients with Cush-
ing’s disease and acromegaly.25 As such, 
more aggressive resection of functional 
tumors invading the cavernous sinus is 
often appropriate with the goal of either 
achieving complete resection or reduc-
tion of the residual tumor volume for 
subsequent radiosurgery.
Surgical approaches to the cavernous 
sinus include the medial and lateral 
approaches. The medial approach (Figure 
5A) is a continuation of the standard 
transsphenoidal approach but involves 
following the adenoma through the 
cavernous sinus medial wall breach. To 
increase access to the cavernous sinus, 
the sellar bony opening is extended 
laterally across the anterior face of the 
carotid artery. Intrasellar tumor resec-
tion is completed before entry into 
the cavernous sinus. The cavernous 
sinus should be approached through 
the contralateral nare using angled 
ring curettes and suctions to optimize 
the angle of attack with visualization 
performed using a 30-70° endoscope. 
covered with a layer of absorbable 
hemostatic cellulose to promote epithe-
lialization. Small dural defects resulting in 
low-flow CSF leakage are repaired with a 
synthetic dural substitute inlay graft placed 
under the leaflets of the dural opening and 
supplemented with a thin layer of dural 
sealant (Figure 4). For larger diaphragmatic 
defects, the arachnoid is directly repaired 
with an onlay dural substitute covering 
the site of leakage followed by place-
ment of an inlay dural graft and sealant. 
For EEA and high-flow leaks related to 
entry into the ventricular system, a NSF is 
used to buttress the synthetic dural graft 
repair or a fascia lata “button” graft repair 
as previously described.25 Lumbar drain 
placement and nasal packing are rarely 
necessary for CSF leak avoidance.
Symmetric descent of the diaphragm 
into the sella is usually indicative of optic 
chiasm decompression and failure of the 
diaphragm to descend or asymmetric 
descent should prompt further search 
for residual tumor. After final confir-
mation of complete tumor resection, 
meticulous hemostasis is achieved with 
the use of hemostatic matrix agents and 
gentle packing with cottonoids. In our 
experience, the most common reason 
for postoperative hemorrhage has been 
incomplete tumor resection and absolute 
hemostasis is necessary when residual 
tumor is expected. 
A graded approach to dural reconstuction 
is performed and in the absence of any 
intraoperative CSF leakage as confirmed 
by Valsalva maneuver, the dura is simply 
Figure 4.  Dural reconstruction. 
A. Intrasellar cavity after tumor resection with incompetent diaphragma sellae and 
low-flow CSF leakage. B. Placement of “inlay” synthetic dural substitute beneath leaves 
of dura. C. Supplementation of dural graft with tissue sealant. D. Intraoperative view after 
dural reconstruction with watertight closure.
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aspect of the cavernous sinus. Careful 
evaluation of the preoperative CT images 
helps determine the access to the lateral 
cavernous sinus and in some patients 
with large, well-pneumatized sphenoid 
sinuses, access may be achieved through 
the lateral sphenoid sinus recess without 
extensive pterygoid drilling. After carotid 
artery localization with the micro-
Doppler, the dura is opened sharply and 
tumor resected. A multi-layered closure 
with NSF coverage is then performed. 
The most feared and potentially devas-
tating morbidity with the cavernous 
sinus approaches is ICA rupture with 
the likelihood of injury increased with 
fibrous tumors and prior irradiation. 
Management of carotid artery injury will 
be more extensively discussed in other 
chapters of this edition but typically 
requires intraoperative control using 
direct compression followed by vessel 
sacrifice in the interventional angiog-
raphy suite.26 
CONCLUSION
Endoscopy represents the most recent 
evolution of transsphenoidal surgery. 
Although the endoscopic approach 
has not been proven to be superior to 
the classical microscopic approach 
for resection of pituitary adenomas, 
the benefits of endoscopy become 
most apparent during removal of large, 
invasive tumors where the panoramic 
visualization afforded by the endoscope 
allows for more complete resections 
to be performed. As neurosurgeons 
continue to take on the challenge of 
endoscopy and surmount their learning 
curve, endoscopic transsphenoidal 
surgery for pituitary adenomas will 
certainly become the standard. 
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INTRODUCTION
In 2017, it is estimated that 26,070 patients will be diagnosed with a malignant primary 
brain tumor in the United States, with more than half having the diagnosis of glioblas-
toma (GBM).1 Magnetic resonance imaging (MRI) is a widely utilized examination in the 
diagnosis and post-treatment management of patients with glioblastoma; standard 
modalities available from any clinical MRI scanner, including T1, T2, T2-FLAIR, and 
T1-contrast-enhanced (T1CE) sequences, provide critical clinical information. In the 
last decade, advanced imaging modalities are increasingly utilized to further charac-
terize glioblastomas. These include multi-parametric MRI sequences, such as dynamic 
contrast enhancement (DCE), dynamic susceptibility contrast (DSC), diffusion tensor 
imaging (DTI), functional imaging, and spectroscopy (MRS), to further characterize 
glioblastomas, and significant efforts are ongoing to implement these advanced imaging 
modalities into improved clinical workflows and personalized therapy approaches. A 
contemporary review of standard and advanced MR imaging in clinical neuro-oncologic 
practice is presented.
Initial diagnosis and surgical management
Most patients with glioblastoma undergo computed tomography of the brain upon 
initial presentation. Once a mass is identified and hemorrhage is excluded, a contrast-
enhanced MRI is typically ordered, with standard T1, T2, FLAIR, and contrast-enhanced 
T1 (T1CE) sequences.2,3 Many institutions will also capture gradient echo and diffusion 
sequences. Maximal safe debulking surgery is recommended as the initial standard of 
care. Neurosurgeons will often utilize high-resolution MRI (0.5 – 1.2mm slice thickness) 
for surgical planning and intraoperative guidance, as well as to make the determination 
of how aggressively to resect based on risk of toxicity to nearby eloquent regions.4 
Standard imaging also can identify other important characteristics of the mass in situ, 
including the amount of necrosis, compression of the surrounding normal tissue, and 
midline deviation.
A recent meta-analysis of over 40,000 glioblastoma patients demonstrated that gross-
total resection was associated with improved survival as compared to subtotal resection.5 
Historically, the determination of gross-total resection was made in the operating room 
by the neurosurgeon. However, in the modern era, the practice of obtaining a post-
operative contrast-enhanced MRI within 24-48 hours of surgery has become routine 
after publication of a study showing that radiological determination of the extent of 
resection via MRI had prognostic significance.6 Several series have attempted to quantify 
a threshold value for the extent of resection as a guide for neurosurgeons, utilizing 
the amount or enhancing tumor present in the preoperative and post-operative T1CE 
images. These series report thresholds ranging from 70% to 100%7-9, with the caveats 
that they were obtained retrospectively. To date, no formal threshold is recommended 
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other than “maximal safe resection” as 
mentioned previously.
Standard preoperative images can be 
analyzed for macroscopic shape and 
location features that are associated with 
improved survival,10-13 providing potential 
biomarkers that may be utilized in strati-
fying patients in clinical trials.
Advanced MR imaging sequences have 
utility in the preoperative domain as 
well. Functional imaging (fMRI) has 
been particularly useful in preoperative 
surgical planning in cases where tumors 
or their resection may disrupt eloquent 
areas. Many patients who were once 
felt to be unresectable due to uncer-
tain risk of neurologic compromise are 
now candidates for more aggressive 
resection after functional mapping.14 
Diffusion tensor imaging (DTI) generates 
rich white matter tractography images 
which may guide neurosurgical plan-
ning15 and can help distinguish between 
post-operative vascular damage and 
residual enhancing tumor.16 Dynamic 
contrast-enhanced (DCE) sequences 
in the preoperative setting measure 
pharmacokinetic parameters of contrast 
uptake, which may be associated with 
early disease progression and survival.17 
Dynamic susceptibility contrast (DSC) MR 
imaging may be helpful in preoperative 
diagnosis18 of malignant lesions. Imaging 
features extracted from standard and 
advanced preoperative MR sequences 
can predict survival, molecular subtype, 
and mutational status in glioblastoma,19,20 
potentially enhancing the set of imaging 
biomarkers available to clinicians.
Post-operative imaging and 
radiation planning
After maximal safe resection, which is 
evaluated on immediate post-operative 
MRI, the standard of care for patients 
with glioblastoma is chemoradiation 
with concurrent temozolomide, after 
the results of a large randomized Phase 
III trial.21 Typically, chemoradiation 
begins 3-6 weeks after surgery to allow 
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Figure 1 Figure 2 Figure 3 Figure 4
Figure 1. Axial CT image at the level of basal 
ganglia demonstrates a large heterogeneous 
mass in the right frontal lobe with mass effect 
on the right lateral ventricle and leftward shift 
of midline. Ct, computed tomography.
Figure 2. Axial FLAIR weighted image at the 
level of basal ganglia demonstrates heteroge-
neous mass centered in the right frontal lobe 
and basal ganglia with surrounding infiltrating 
signal abnormality ‘FLAIR envelope’ which 
extends medially across the corpus callosum 
posteriorly in the insular region. The ‘FLAIR 
envelope’ is typically a manifestation of 
combination of tumor infiltration and edema. 
There is associated mass effect on the right 
ventricle and leftward midline shift. FLAIR, 
fluid-attenuated inversion recovery.
Figure 3. Axial gradient echo (GRE) image 
depicts multiple foci of hypointense signal 
‘susceptibility artifacts’ within the right frontal 
mass compatible with intra-tumoral blood 
products.
Figure 4. Post gadolinium based contrast 
administration T1 weighted axial image 
(T1CE). There is heterogeneous irregular 
peripheral enhancement associated with 
the right frontal lobe mass with central 
non-enhancing area, consistent with 
necrosis. Of note are additional patchy areas 
of enhancement in the right anterior frontal 
lobe and right basal ganglia region. These 
additional areas of enhancement lie within 
the previously described region of ‘FLAIR 
envelope’. FLAIR, fluid-attenuated inversion 
recovery; T1CE, T1 contrast-enhanced.
Figure 5. BOLD fMRI for localization of hand 
sensorimotor cortex in a patient with right 
frontal glial neoplasm. BOLD fMRI data is 
superimposed on sagittal FLAIR weighted 
image for anatomic localization. In the right 
hemisphere, the hand sensorimotor cortex 
(arrow) is located along the posterosuperior 
aspect of the frontal mass and is separated by 
less than one gyrus distance. fMRI, functional 
magnetic resonance imaging; FLAIR, fluid-
attenuated inversion recovery.
Figure 6. BOLD fMRI for localization of 
tongue sensorimotor cortex. BOLD fMRI data 
is superimposed on axial FLAIR weighted 
image for anatomic localization. In the right 
hemisphere, the area of 
activation (arrow), tongue sensorimotor 
cortex is in immediate proximity of the poste-
rior margin of the right frontal mass. FLAIR 
envelope seems to extend into this region 
of activation. fMRI, functional magnetic 
resonance imaging; FLAIR, fluid-attenuated 
inversion recovery.
Figure 7. BOLD fMRI for localization of 
Broca’s area in a patient with right frontal 
glial neoplasm. There is bilateral Broca’s 
area activation on sentence completion and 
verb generation tasks (arrows), with the right 
hemispheric area of activation located at the 
anteroinferior aspect of tumor within one 
gyrus distance. fMRI, functional magnetic 
resonance imaging.
Figure 8. Color fractional anisotropy map 
superimposed on axial FLAIR weighted 
image. There is loss of fractional anisotropy 
in the expected region of right corticospinal 
tract (arrow, blue colored fibers). This tract is 
located at the posteromedial margin of the 
FLAIR envelope. Loss of fractional anisotropy 
may be related edema, infiltration by tumor 
or displacement. FLAIR, fluid-attenuated 
inversion recovery.
Figure 5 Figure 6 Figure 7 Figure 8
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along with fractional anisotropy measure-
ments from diffusion images, ADC values 
may be associated with poor response to 
treatment and worse survival among high 
grade glioma patients.29 Diffusion and 
perfusion parameters, when combined with 
standard MR sequences, may allow radia-
tion oncologists to better characterize the 
highest-risk regions to include in high-dose 
target volumes, utilizing macroscopi-
cally visible features30 as well as radiomic 
features.31 Voxel-based MR spectroscopy 
(MRS) and whole-brain spectroscopic MRI 
(sMRI) may identify regions of tumor infiltra-
tion and areas at high risk of recurrence;32 
regions with metabolic abnormalities on 
sMRI are correlated with intraoperative 
tissue samples showing increased immuno-
histochemical staining for neoplastic cells.33
Response Assessment
As demonstrated at any multidisciplinary 
tumor board, imaging is of utmost impor-
tance in the interpretation of the response to 
treatment in glioblastoma. The first widely-
adopted set of guidelines for standardizing 
the assessment of treatment response that 
utilized MR imaging was the Macdonald 
criteria,34 which used clinical parameters in 
conjunction with imaging measurements to 
classify responses into four broad catego-
ries (complete response, partial response, 
stable disease, and progressive disease). 
MR imaging to define the at risk target 
volumes and organs at risk.
It is common to identify shifting of brain 
parenchyma on planning CT in the weeks 
after craniotomy as the normal brain 
tissue expands to fill the space taken out 
by the tumor. One study demonstrated a 
4mm shift in the position of the treatment 
isocenter between CT and MRI-based 
target delineation,25 even with only a few 
days between studies. The magnitude 
of the shift can be several centime-
ters, resulting in inaccurate registration 
between post-operative MRI and simula-
tion CT. Many institutions have begun the 
practice of obtaining repeat MRI at the 
time of simulation to better characterize 
the soft tissues for target delineation.
Advanced imaging at this time point may 
play a role in radiation planning. A Polish 
study demonstrated the discordance 
between gross tumor volume (GTVs) 
delineated from MRI as compared to 
18F-fluoroethylthyrosine-PET (FET-PET), a 
functional imaging modality; FET-PET was 
better associated with the site of eventual 
failure, suggesting that traditional target 
volumes may not be adequate.26 ADC 
maps generated from diffusion imaging 
can identify areas of restricted diffusion 
that may predict for areas of eventual 
recurrence with high concordance;27,28 
for adequate post-operative recovery. 
Radiotherapy planning includes registra-
tion (aka “fusion”) of the post-operative 
MRI (T1CE and FLAIR sequences) with the 
planning simulation CT, which allows for 
delineation of the FLAIR abnormality and 
residual enhancement in treatment plan-
ning. Guidelines for these delineations 
exist, but substantial variation is observed 
among practitioners from different coop-
erative groups (e.g., RTOG22 vs. EORTC23), 
and even among practitioners from one 
country,24 but all utilize post-operative 
Figure 11.  
Pre- and immediate post-operative (at 24 hours) axial t1CE weighted images. On post-oper-
ative image, there is minimal residual enhancement particularly along the medial aspects of 
the surgical site, concerning for minimal residual tumor. Majority of the hyperintense signal 
in the right parieto-occipital region is related to blood post-operative blood products. T1CE, 
T1-weighted contrast-enhanced.
Figure 10.  
Dynamic susceptibility contrast (DSC) 
perfusion weighted image. There is 
increase in rCBV (relative cerebral blood 
volume) in the region of right frontal 
mass (Figures 1-4), a finding favoring high 
grade neoplasm.
Figure 9.  
Tractography image demonstrates the 
intimate relationship of right frontal mass with 
the corticospinal tract (blue colored fibers).
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Challenges and limitations of the 
Macdonald criteria became apparent 
as imaging modalities revealed more 
details about gliomas and their response 
to treatment. The importance of non-
contrast-enhancing regions of abnormality 
has become better understood; for 
example, changes in the volume of 
Figure 13. 
Axial FLAIR and post contrast T1 weighted 
images demonstrate a large heteroge-
neously enhancing mass in the right 
parieto-occipital region with surrounding 
FLAIR hyperintense signal, compatible 
with high grade glial neoplasm. FLAIL, 
fluid-attenuated inversion recovery.
Figure 14. 
Immediate post-operative  
(at 24 hours) axial post contrast T1 weighted 
image. There is minimal residual peripheral 
enhancement particularly along the medial 
aspects of the surgical site concerning for 
small amount of residual tumor.
Figure 12. 
Single voxel MR spectroscopy at long TE (288 ms) acquired through the right temporoparietal 
region mass with imaging appearance compatible with glial neoplasm. There is markedly 
elevated choline (resonates at 3.2 ppm) with markedly decreased NAA (resonates at 2 ppm), a 
finding consistent with high grade glial neoplasm. MR, magnetic resonance.
Figure 15. 
Immediate post-operative (at 24 hours) axial 
post contrast T1 weighted image. There is 
minimal residual peripheral enhancement 
particularly along the medial aspects of the 
surgical site concerning for small amount of 
residual tumor.
Figure 16.
Follow up of a case of glioblastoma on 
therapy. Axial FLAIR weighted image demon-
strates a large area of infiltrating hyperintense 
signal abnormality in right temporo-occipital 
region, with associated mass effect and left-
wards shift of midline. FLAIR, fluid-attenuated 
inversion recovery.
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immunotherapy response assessment 
in neuro-oncology (iRANO) criteria,42 
which attempted to provide standardized 
guidelines for the determination of tumor 
progression in the setting of immune-
related therapy. 
MRI imaging features have the poten-
tial to predict treatment response to 
specific modalities of treatment. Relative 
cerebral blood volume and dynamics 
parameters (K¬trans and Ve), measured 
by perfusion-weighted MR imaging and 
other features may predict treatment 
response to standard chemoradiation 
and VEGF inhibitors,43-45 prior to initiation 
of therapy. Radiomic features derived 
from these images have been shown to 
have predictive value as well.46 
CONCLUSIONS
The volume of medical imaging data 
continues to grow at an exponential rate. As 
MR imaging becomes more cost-effective 
and the adoption of advanced MR modali-
ties becomes more widespread, it will 
become more critical than ever to incor-
porate advanced imaging and the power 
of large datasets into the management 
of glioblastoma. We anticipate that these 
changes will include not only the utilization 
of new MR sequences but also novel image 
analysis techniques, including radiomic 
analysis, to better drive treatment decision-
making, with the goal of improving clinical 
outcomes in glioblastoma.
is most commonly observed in patients 
whose tumors harbored a methylated 
MGMT promoter region,36 and makes 
accurate assessment of response difficult, 
especially in the setting of clinical trials 
attempting to answer the question of effi-
cacy of novel treatment regimens. Some 
medications, including anti-angiogenic 
drugs and immunologic agents, elicit 
unique radiographic changes which may 
mask accurate response assessment as well. 
These limitations, among others, led to the 
development of a new set of guidelines 
developed by the Response Assessment 
in Neuro-Oncology (RANO) working 
group,37 which incorporates more infor-
mation from MR imaging, including FLAIR 
sequence changes, into the objective 
assessment. The RANO criteria have been 
incorporated into clinical trials and daily 
clinical practice, allowing better apples-
to-apples comparisons.38 
Clinical trials in the last decade demon-
strated the benefit of bevacizumab, an 
anti-angiogenic monoclonal antibody, in 
recurrent glioblastoma.39 The radiographic 
appearance of malignant gliomas changes 
dramatically after treatment with bevaci-
zumab as a result of changes in vessel 
permeability and contrast dynamics.40 
Initial studies showed the difficulty in 
distinguishing these radiographic changes 
from true tumor effect; the temporal 
dynamics were also unclear.41 These 
issues led to the development of the 
hyperintensity on post-treatment FLAIR 
imaging, relative to baseline, are correlated 
with improved survival.35 Furthermore, 
some glioblastomas demonstrate imaging 
changes consistent with progression under 
the Macdonald criteria, but upon repeat 
surgical intervention, viable tumor cannot 
be identified in the resection specimen, 
suggesting that the adjuvant treatment 
may actually be having a positive effect that 
eludes detection on conventional imaging. 
This finding, termed “pseudoprogression,” 
Figure 17.
Axial T1CE image depicts an area of 
heterogeneous enhancement in right 
temporal lobe within the region of FLAIR 
signal abnormality. FLAIR, fluid-attenuated 
inversion recovery. T1CE, T1-weighted 
contrast-enhanced.
Figure 18.
Axial post-contrast T1 (T1CE) images at 8 months. There is a large heterogeneously enhancing 
mass in the right parieto-occipital region at the operative site. There is interval development of 
multiple enhancing nodules along the ependymal surface of ventricles, particularly along the 
right frontal and temporal horn, and roof of fourth ventricles. These findings are compatible with 
tumor progression. T1CE, T1-weighted contrast-enhanced.
Figure 19.
On dynamic susceptibility contrast (DSC) 
perfusion weighted imaging, the area 
of signal abnormality predominantly 
demonstrates low relative cerebral blood 
volumes. The overall findings were consis-
tent with pseudoprogression.
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ABSTRACT
Background: Stereotactic radiosurgery (SRS) has emerged as an important modality for 
the treatment of intracranial metastases. There are currently few established guidelines 
delineating indications for SRS use and fewer still regarding plan evaluation in the treat-
ment of multiple brain metastases.
Methods: An 18 question electronic survey was distributed to radiation oncologists 
at National Cancer Institute (NCI) designated cancer centers in the US (60). Centers 
without radiation oncologists were excluded. Physicians who indicated that they do 
not prescribe SRS were excluded from the remaining survey questions. Sign test and 
Chi-square test were used to determine if responses differed significantly from random 
distribution.
Results: 116 of the 697 radiation oncologists surveyed completed the questionnaire, 
representing 51 institutions. 62% reported treating patients with brain metastases using 
SRS. Radiation oncologists prescribing SRS most commonly treat CNS (66.2%) and lung 
(49.3%) malignancies. SRS was used more frequently for <10 brain metastases (73.7%; 
p<.0001) and whole brain radiation therapy (WBRT) for >10 brain metastases (82.5%; 
p<.0001). The maximum number of lesions physicians were willing to treat with SRS 
without WBRT was 1-4 (40.4%) and 5-10 (42.4%) (p<.0001 compared to 11-15, 16-20 
and no limit). The most important criteria for choosing SRS or WBRT were number of 
lesions (p<.0001) and performance status (p=.016). The most common margin for SRS 
was 0 mm (49.1%; p=.0021). The most common dose constraints other than critical 
structure was conformity index (84.2%) and brain V12 (61.4%). The LINAC was the most 
common treatment modality (54.4%) and mono-isocenter technique for multiple brain 
metastases was commonly used (43.9%; p=.23). Most departments do not have a policy 
for brain metastases treatment (64.9%; p=.024). 
Conclusions: This is one of the first national surveys assessing the use of SRS for brain 
metastases in clinical practice. These data highlight some clinical considerations for 
physicians treating brain metastases with SRS.
Summary: This is among the first national surveys to assess the use of SRS for brain 
metastases in clinical practice. Specifically, radiation oncologist reported increasingly 
using SRS instead of WBRT for treating 
<10 metastases, with the LINAC being 
the most common modality. Further, 
treatment parameters considered the 
most important included 0 mm margins, 
conformity index, brain V12, and mono-
isocenter technique for multiple brain 
metastases. These results may provide 
context regarding the use of SRS for brain 
metastases in clinical practice.
INTRODUCTION
Brain metastases are a significant cause 
of morbidity and mortality among 
oncologic patients, affecting 20-40% 
of this population.1 Several therapeutic 
strategies for intracranial metastases 
exist, including stereotactic radiosurgery 
(SRS), whole brain radiotherapy (WBRT), 
surgical resection and supportive care 
with steroids, though systemic therapy 
remains an option for patients with 
selected cancers.2 WBRT was historically 
the treatment modality of choice for 
brain metastases with or without surgical 
resection.3,4 Technological improvements 
in Gamma Knife and LINAC-based SRS 
coupled with data indicating decreased 
cognitive toxicity with SRS5, have led to 
increased utilization of SRS6. Although 
evidence-based clinical practice guide-
lines exist for the use of SRS for brain 
metastases,7-12 there are comparatively 
fewer reports that study specific aspects 
of SRS plan evaluation or if current 
use reflects the recommendations of 
professional societies. In that context, 
the current study represents one of the 
few national surveys which specifically 
investigates these issues to clarify the 
role of SRS for intracranial metastases in 
clinical practice.
MATERIALS AND METHODS
Study Design 
An 18 question, non-incentivized elec-
tronic survey was distributed to radiation 
oncologists at National Cancer Institute 
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Stereotactic Radiosurgery Survey 
five years. While the survey did not eval-
uate the role insurers play in physicians’ 
decision making, private insurance typi-
cally recognizes the role of SRS in treating 
multiple brain metastases with no clear 
maximum identified.18 Additionally, citing 
a growing body of literature regarding 
safety and efficacy, current National 
Comprehensive Cancer Network (NCCN) 
recommendations for SRS alone do not 
specify a maximum number of lesions.19 
Knisely et al first examined the use of 
SRS in clinical practice several years ago; 
physicians at two conferences hosted by 
national stereotactic radiosurgery soci-
eties were asked to fill a questionnaire, 
with a majority of respondents consid-
ering it “reasonable” to treat greater 
than 5 metastases with SRS alone.20 
More recently, Sandler et al evalu-
ated practicing physicians’ “cutoff” for 
treating brain metastases with SRS alone 
versus WBRT, among other scenarios.21 
Importantly, they found CNS-specialists 
to be comfortable treating a mean of 
8.1 lesions compared to 5.6 and 5.1 
lesions for low-volume CNS specialists 
and non-CNS specialists respectively.21 
While our survey did not stratify SRS use 
according to specialization, our results 
reflect a similar trend among physicians 
at a national level for treating greater than 
five lesions with SRS alone. 
Notably, recent American Society for 
Therapeutic Radiology and Oncology 
(ASTRO) Choosing Wisely guidelines 
recommend against using adjuvant 
WBRT with SRS, and instead recom-
mend SRS monotherapy for brain 
metastases.12,22 However, no guidance is 
provided regarding the SRS plan evalua-
tion. The present study identifies several 
parameters in current SRS use for brain 
metastasis in practice, including the use 
of 0 mm margins, conformity index, brain 
V12, and the mono-isocenter technique 
for multiple brain metastases. While our 
survey did not specifically assess the 
values used for each parameter, retro-
spective data indicate that V12 greater 
than 10.9 cm3 is associated with a 51% 
1 year risk of radionecrosis.23 Likewise, 
other treatment parameters appear to 
play an important role in the development 
of a safe and effective treatment plan.
The overall response rate was low for 
this study, introducing the potential for 
number of lesions (p<.0001), histology 
(p=.0014), performance status (p=.016) 
and location (p<.0001) as determined by 
sign-test. Leptomeningeal disease was 
statistically significant versus all other 
choices as the predominant contraindi-
cation to prescribing SRS without WBRT 
(93%; CI [83-98%]). 
Treatment Modality and Planning 
LINAC (54.4%) was more commonly 
used than the CyberKnife (14.0%) or 
Gamma Knife (31.6%) for SRS treat-
ment (p=.0009). The mono-isocenter 
technique for multiple brain metastases 
was commonly used (43.9%; p=.23). The 
most common margin for SRS was 0 mm 
(49.1%; p=.0021), with 38.6% and 12.3% 
prescribing a 1 mm and 2 mm margin, 
respectively. The most common dose 
constraints other than critical structure 
were conformity index (84.2%) and V12 
(61.4%). Diameter, volume and histology 
of lesion were all ranked as significant 
in determining the SRS prescription 
dose (sign-test, p<.0001, p=.001 and 
p<.0001, respectively). Notably, most 
departments do not have a policy in 
place for treating brain metastases with 
SRS (64.9%; p=.024). 
DISCUSSION
Despite increasing use of SRS to treat 
brain metastases, little exists in terms 
of guidance for physicians using this 
modality. Moreover, our data indicate that 
most departments do not have policies 
governing SRS use. Importantly, no clear 
guidelines exist regarding the maximum 
number of metastases for which SRS is 
recommended, despite a historically-
used cutoff of 4 in clinical trials.5,13,14 In 
this study, 42.4% of respondents reported 
using SRS for patients with 5-10 metas-
tases and 17.5% of respondents offering 
it for more than 10 lesions without WBRT. 
Thus, a significant number of respondents 
are using SRS for more than the standard 
4 lesions. In total, 73.7% of respondents 
reported using SRS more often for <10 
metastasis, and 82.5% used WBRT more 
often for >10 lesions. These physicians 
may be influenced by a shifting paradigm 
towards SRS alone for a greater than 5 
or greater than 10 lesions.15-17 Indeed, 
the majority of respondents reported 
increasing their use of SRS over the last 
designated cancer centers in the United 
States (60). Centers without radiation 
oncologists were excluded. The total 
number of physicians contacted was 697. 
Physicians who reported not prescribing 
SRS were not invited to complete 
remaining survey questions. Per institu-
tional policy, this study was IRB-exempt.
Statistical Analysis 
Depending on type of question, 95% 
confidence interval (estimate of propor-
tion), sign test (difference from expected 
mean) or Chi-square test (difference 
from expected distribution) were used 
to determine if responses differed 
significantly from random distribution. 
All data analyses were completed using 
Stata software and a P value < 0.05 was 
considered to be statistically significant.
RESULTS
Response and Demographic Data 
All survey results are reproduced in 
Table 1. Of 697 physicians surveyed, 118 
(16.9%) responded, with 28.7% reporting 
that they do not treat brain metastases 
with SRS. Respondents represented 51 
different institutions across 28 states 
with varying years of practice experience. 
Indications and Use in Practice 
Respondents primarily treated CNS (66.2%, 
95% CI [54-77%]); lung was numerically 
the second most commonly treated 
disease site (49.3%). SRS (73.7%) was 
used more frequently than WBRT (10.5%) 
for <10 brain metastases (p<.0001) while 
WBRT (82.5%) was used more frequently 
than SRS (5.3%) for >=10 brain metas-
tases (p<.0001). The maximum number 
of lesions physicians were willing to treat 
with SRS without WBRT in the treatment 
session was 1-4 (40.4%) and 5-10 (42.4%) 
(p<.0001; compared to 11-15, 16-20 and 
no limit). Most physicians reported they 
would not treat more than 10 lesions 
over multiple sessions with SRS (43.9%; 
p=.0003) but 19.3% reported there was 
no limit to the number they would treat. 
Physicians indicated that their practice 
had changed in the past 5 years by more 
frequently using SRS without WBRT 
(84.2%) and SRS without other treatments 
(i.e. surgery or WBRT; 82.5%). Criteria used 
to determine SRS versus WBRT use were 
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response bias. Despite this potential 
limitation, emerging research suggests 
that low response rates are not inher-
ently associated with inaccurate results 
or nonresponder bias.24,25 Moreover, the 
wide geographic spread and distribution 
of practice experience among respon-
dents suggests that the current sample 
was representative of the academic field 
at large. As this survey was distributed to 
physicians practicing at NCI-designated 
cancer centers however, the responses 
may not be reflective of the patterns 
of SRS use in private practice. Another 
potential limitation of the survey was 
that it did not account for patient volume 
per institution, which may be a surrogate 
for expertise in SRS and could influence 
aggressiveness in treating multiple brain 
metastases. Furthermore, individual 
practitioners were not asked about their 
patient volumes, which may be a surro-
gate for clinical versus research time in an 
academic setting and therefore influence 
management preferences. Future studies 
will be needed to continue to address 
these issues and refine clinical practice. 
CONCLUSIONS
To our knowledge, this is among the first 
national assessments of the use of SRS 
for brain metastases in clinical practice 
in the U.S. The data indicate that radia-
tion oncologists are increasingly using 
SRS for the treatment of intracranial 
lesions, even in situations which were 
historically treated with WBRT. Treatment 
parameters considered most by respon-
dents include 0 mm margins, conformity 
index, brain V12, and a mono-isocenter 
technique for multiple brain metastases. 
These data may reveal areas that require 
guidance and instruction from coopera-
tive group committees.
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State Police, a spine surgeon for the U.S. Olympic rowing team, 
and is a past president of the New Jersey Neurosurgical Society.
He has performed more than 6,000 major intracranial and 
spinal operations, with particular attention to brain tumors, 
cerebral aneurysms, spinal stenosis and herniated cervical and 
lumbar discs.
Dr. Chiurco is a 1967 graduate of the Sidney Kimmel Medical 
College.
The Jefferson family had a double celebration on July 19, 2017, 
to thank Dr. and Mrs. Anthony Chiurco for establishing the 
Anthony Alfred Chiurco, MD Professor in the Department of 
Neurological Surgery, and to recognize the neurosurgical talents 
of Dr. David Andrews, who was installed as the first Anthony 
Alfred Chiurco Professor.
The celebration served as a reminder of how Jefferson improves 
lives every day through philanthropic partnerships that estab-
lish initiatives such as the Vickie and Jack Farber Institute for 
Neuroscience. The investiture was also a great opportunity to 
acknowledge Dr. Chiurco’s Class of 1967, which is celebrating 
its 50-year reunion this year. 
ABOUT DAVID W. ANDREWS, MD
As a neurosurgeon practicing neuro-oncologic neurosurgery 
over a 28-year period, Dr. Andrews has vast experience in the 
diagnosis, management and treatment of brain tumors. He 
established the Brain Tumor Division in the Department of 
Neurological Surgery at Thomas Jefferson University in 1995, 
and as division chief has built a world-class group including 
four neurosurgeons and two neuro-oncologists currently 
performing more than 1,200 major cases a year. While training 
as a resident at New York-Presbyterian/Weill Cornell Medicine 
he also completed a one-year fellowship at Memorial Sloan-
Kettering Cancer Center.
As a junior attending surgeon, he was awarded a K11 Physi-
cian Scientist Award and studied the molecular pathogenesis 
of malignant gliomas under Dr. Carlo Croce. Currently he is 
the sponsor investigator and chief architect of a novel FDA-
approved phase 1b immunotherapy trial for patients with newly 
diagnosed glioblastoma, which is achieving remarkable results 
in the highest vaccine cohort.
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Recent Publications
Selected Recent Neuro-Oncology 
Publications
• Belinsky I, Murchison AP, Evans JJ, Andrews DW, Farrell 
CJ, Casey JP, Curtis MT, Nowak Choi KA, Werner-Wasik M, 
Bilyk JR. Spheno-Orbital Meningiomas: An Analysis Based 
on World Health Organization Classification and Ki-67 
Proliferative Index. Ophthalmic Plastic and Reconstructive 
Surgery. 2017.
• Li J, Shi W, Andrews D, Werner-Wasik M, Lu B, Yu Y, Dicker 
A, Liu H. Comparison of Online 6 Degree-of-Freedom 
Image Registration of Varian TrueBeam Cone-Beam CT 
and BrainLab ExacTrac X-Ray for Intracranial Radiosurgery. 
Technology in Cancer Research and Treatment. 2017.
• Alyemni D, Miller AF, Couto P, Athas D, Roberts AL, Rufail M, 
Andrews DW, Strayer DS, Kenyon LC. Histopathologic iden-
tification of Trypanosoma cruzi (Chagas’) encephalitis in an 
AIDS patient. Human Pathology: Case Reports. 2017.
• Hernández-Estrada RA, Kshettry VR, Vogel AN, Curtis MT, 
Evans JJ. Cholesterol granulomas presenting as sellar 
masses: a similar, but clinically distinct entity from craniopha-
ryngioma and Rathke’s cleft cyst. Pituitary. 2017.
• Gill KS, Hsu D, Tassone P, Pluta J, Nyquist G, Krein H, Bilyk J, 
Murchison AP, Iloreta A, Evans JJ, Heffelfinger RN, Curry JM. 
Postoperative cerebrospinal fluid leak after microvascular 
reconstruction of craniofacial defects with orbital exentera-
tion. Laryngoscope. 2017.
• Shi W, Blomain ES, Siglin J, Palmer JJ, Dan T, Wang Y, 
Werner-Wasik M, Glass J, Kim L, Bar Ad V, Bhamidipati D, 
Evans JJ, Judy K, Farrell CJ, Andrews DW. Salvage frac-
tionated stereotactic re-irradiation (FSRT) for patients with 
recurrent high grade gliomas progressed after bevacizumab 
treatment. J Neuro-Oncology. 2017.
• Williams NL, Wuthrick EJ, Kim H, Palmer JD, Garg S, 
Eldredge-Hindy H, Daskalakis C, Feeney KJ, Mastrangelo MJ, 
Kim LJ, Sato T, Kendra KL, Olencki T, Liebner DA, Farrell CJ, 
Evans JJ, Judy KD, Andrews DW, Dicker AP, Werner-Wasik M, 
Shi W. Phase 1 Study of Ipilimumab Combined With Whole 
Brain Radiation Therapy or Radiosurgery for Melanoma 
Patients With Brain Metastases. International Journal of 
Radiation Oncology Biology Physics. 2017.
• Park HR, Kshettry VR, Farrell CJ, Lee JM, Kim YH, Won TB, 
Han DH, Do H, Nyguist G, Rosen M, Kim DG, Evans JJ, 
Paek SH. Clinical Outcome After Extended Endoscopic 
Endonasal Resection of Craniopharyngiomas: Two-Institution 
Experience. World Neurosurgery. 2017.
• Do H, Kshettry VR, Siu A, Belinsky I, Farrell CJ, Nyquist 
G, Rosen M, Evans JJ. Extent of Resection, Visual, and 
Endocrinologic Outcomes for Endoscopic Endonasal 
Surgery for Recurrent Pituitary Adenomas.  World 
Neurosurgery. 2017.
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Brain Aneurysm and AVM Support Group at Jefferson
Support Groups
When Third Wednesday of every month (September through June)
Time 6:30-8:30 p.m.
Place  900 Walnut Street, 3rd Floor, Conference Room 
 Philadelphia, PA 19107
Moderator/  
Secretary Jill Galvao
Parking  Complimentary parking is provided in the parking garage 
located in the JHN Building (Jefferson Hospital for 
Neuroscience) on 9th Street (between Locust & Walnut)
Information For additional information please call: 215-503-1714
N eurosurgical Emergency  Hotline 
 Jefferson Hospital for Neuroscience 
Aneurysms • AVMs • Intracranial Bleeds
7 day • 24 hour coverage
1-866-200-4854
The Brain Aneurysm and AVM (arteriovenous 
malformation) Support Group provides 
support for individuals, family members and 
friends who have been affected by cerebral 
aneurysms, subarachnoid hemorrhage and 
AVMs. The purpose of the group is to gain and 
share knowledge and understanding of these 
vascular anomalies and the consequences of 
these disease processes. The group provides 
mutual support to its members by creating an 
atmosphere that engenders active listening 
and sincere and thoughtful speech within a 
caring environment.
The Brain Tumor Support Group at Jefferson
The Delaware Valley Brain Tumor Support 
Group at Jefferson provides an opportunity 
for patients and their families to gain support 
in obtaining their optimum level of well-
being while coping with, and adjusting to 
the diagnosis of brain tumor. Members are 
encouraged to share their support strategies 
so members can confront the challenges 
that this disease process has imposed on 
their lives. The strength gained from group 
can be a source of comfort and hope for 
whatever lies ahead.
When Second Thursday of every month
Time 7-8:30 p.m.
Place   Jefferson Hospital for Neuroscience,  
3rd Floor conference room 
900 Walnut Street Philadelphia, PA 19107
Facilitator Joseph McBride, BSN, RN and Katelyn Salvatore, BSN, RN. 
 215-955-4429 or katlyn.salvatore@jefferson.edu
Parking  Complimentary parking is available at the Jefferson Hospital for 
Neuroscience parking lot.
 Light refreshments and snacks will be served. 
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UPCOMING JEFFERSON  
NEUROSURGERY CME PROGRAMS 
As a part of the Vickie and Jack Farber Institute for Neuroscience at Jefferson, the Department of Neurological 
Surgery is one of the busiest academic neurosurgical programs in the country, offering state-of-the-art treatment to 
patients with neurological diseases affecting the brain and spine, such as brain tumors, spinal disease, vascular brain 
diseases, epilepsy, pain, Parkinson’s disease and many other neurological disorders (Jefferson.edu/Neurosurgery).
As part of a larger educational initiative from the Jefferson Department of Neurological Surgery, the Sidney 
Kimmel Medical College Office of Continuing Medical Education is offering the following continuing professional 
educational opportunities for 2018:
•  7th Annual Neurocritical Care Symposium 
January 26-27, 2018 
Jefferson Alumni Hall, Center City Campus of  
Thomas Jefferson University
•  17th Annual Cerebrovascular Update 
March 15-16, 2018 
Hyatt at the Bellevue, Philadelphia
•  Fundamental Critical Care Support Course 
April 12-13, 2018 
Dorrance H. Hamilton Building, Center City Campus of  
Thomas Jefferson University
•  4th Annual Philadelphia Spine Summit 
May 11, 2018 
Jefferson Alumni Hall, Center City Campus of  
Thomas Jefferson University
•  8th Annual Brain Tumor Symposium 
October 2018 
Philadelphia, PA
•  30th Annual Pan Philadelphia  
Neurosurgery Conference 
December 2018 
Philadelphia, PA
For additional information regarding these and other Jefferson CME  
programs, please visit our website at CME.Jefferson.edu or call the Office  
of CME at 888-JEFF-CME (888-533-3263).  
Sidney Kimmel Medical College at Thomas Jefferson University is  
accredited by the ACCME to provide continuing medical education  
for physicians.
Many of the activities above offer additional CE accreditations.
Follow us on Twitter at @JeffCME 
for updates and new information
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From the nation’s first brain surgery, to our dedicated center  
for ALS research and patient care, Jefferson is at the forefront of  
neuroscience discovery and disease treatment. We’re forging  
ahead again – with the brightest minds in neuroscience, neurology,  
neurosurgery and psychiatry – collaborating as never before within  
one institute – the Vickie and Jack Farber Institute for Neuroscience. 
More brainpower. More breakthroughs. Better outcomes – for you.
1-800-JEFF-NOW | Jefferson.edu/Farber
This is the frontier for neuroscience,  
and we are its pioneers.
PHIL ADELPHIA |  MONTGOMERY COUNT Y |  BUCKS COUNT Y |  SOUTH JERSE Y
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